<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/14.01/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/14.01/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|14|01|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="01"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="14|01" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="/us/md/exec/comar/14.01"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD | Library of Maryland Regulations"/>
    <meta property="og:image" content="/us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14" data-search-heading="">
                  <a href="/us/md/exec/comar/14" title="Title 14 INDEPENDENT AGENCIES">Title 14 INDEPENDENT AGENCIES</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01" data-search-heading="">
                  <span title="Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD">Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="14|01">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/14.01">Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD</h1>
                <h2 id="/us/md/exec/comar/14.01.01" data-order="|14|01|01|" data-ref-path="14|01|01" class="h__chapter">Chapter 01 General Provisions</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: September 6, 2021 (48:18 Md. R. 692)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.01#B" title="">Regulation .01B</a> amended effective December 25, 2023 (50:25 Md. R. 1089)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.01#B" title="">Regulation .01B</a> amended effective December 25, 2023 (50:25 Md. R. 1089); April 28, 2025 (52:8 Md. R. 359)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.02" title=".02 Rules of Construction.">Regulation .02</a> adopted effective December 25, 2023 (50:25 Md. R. 1089)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.03" title=".03 Open Meetings.">Regulation .03</a> adopted effective December 25, 2023 (50:25 Md. R. 1089)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.04" title=".04 Confidential, Trade-Secret, and Proprietary Information.">Regulation .04</a> adopted effective December 25, 2023 (50:25 Md. R. 1089)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05" title=".05 Public Comment Procedures.">Regulation .05</a> adopted effective December 25, 2023 (50:25 Md. R. 1089)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.06" title=".06 Hearing Procedures.">Regulation .06</a> adopted effective April 28, 2025 (52:8 Md. R. 359)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §21-2C-03(f), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/14.01.01.01" data-order="|14|01|01|.01|" data-ref-path="14|01|01|.01" class="h__section">.01 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#A">A.</span> In this subtitle, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(1)">(1)</span> “Abbreviated new drug application (ANDA)” means a submission to the FDA for the review and potential approval for marketing of a generic drug product, including bioequivalence data, as defined in 21 CFR §314.3 and described under 21 CFR §314.50.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(2)">(2)</span> “Accelerated approval” means the FDA drug approval process defined in 21 U.S.C. §356(c)(1)(A).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(3)">(3)</span> “Active ingredient” means a component of a drug that is intended to provide pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, as defined in 21 CFR §314.3.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(4)">(4)</span> “Active moiety” means the molecule or ion responsible for the physiological or pharmacological action of the drug substance, excluding those appended portions of the molecule that cause the drug to be an ester, salt, or other noncovalent derivative of the molecule, as defined in 21 CFR §314.3.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(5)">(5)</span> “Average cost share” means the sum of the cost share of a prescription drug product for each patient, divided by the number of patients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(6)">(6)</span> “Average payor cost per patient” means the sum of the total dollars paid by all payors over the most recent calendar year, divided by the number of patients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(7)">(7)</span> “Average sales price (ASP)” has the meaning stated in 42 U.S.C §1395w-3a(c)(1).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(8)">(8)</span> “Average total out-of-pocket cost” means the sum of all patient total out-of-pocket costs, divided by the number of patients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(9)">(9)</span> “Average wholesale price (AWP)” means the average suggested price paid by a retailer to buy a drug from a wholesaler, excluding price concessions, discounts, and rebates.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(10)">(10)</span> “Biologic” means a biological product, as defined in 42 U.S.C. §262(i)(1).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(11)">(11)</span> “Biologics license application (BLA)” means a request to the FDA to introduce, or deliver for introduction, a biological product, as defined in 21 CFR §600.3(h), into interstate commerce, as regulated under 21 CFR §600-680.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(12)">(12)</span> “Biosimilar” means a biological product, as defined in 42 U.S.C. §262(i)(2), that is produced or distributed in accordance with a biologics license application approved under 42 U.S.C. §262(k)(3).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(13)">(13)</span> “Board” has the meaning stated in Health-General Article, §21-2C-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(14)">(14)</span> “Board staff” means an employee of the Board or a qualified independent third party that has contracted with the Board and is subject to a nondisclosure or confidentiality agreement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(15)">(15)</span> “Brand name drug” has the meaning stated in Health-General Article, §21-2C-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(16)">(16)</span> “Carrier” has the meaning stated in Health-General Article, §19-132, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(17)">(17)</span> “Chair” means the chair of the Board, as provided in Health-General Article, §21-2C-03, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(18)">(18)</span> “Coinsurance” means the percentage of costs paid by the patient after meeting the deductible.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(19)">(19)</span> “Consumer Price Index for All Urban Consumers (CPI-U)” means the measure of the average change over time in the prices paid by urban consumers for a defined market basket of consumer goods and services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(20)">(20)</span> “Copayment” means the set dollar amount that a patient pays for prescriptions or services covered by the patient’s health insurance, separate from the deductible.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(21)">(21)</span> “Cost share” means the patient total out-of-pocket costs divided by gross spending.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(22)">(22)</span> “Deductible” means the set amount a patient pays for health and medical services and products each calendar year before a health insurance plan begins to provide coverage, usually expressed in dollars.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(23)">(23)</span> “Discount” means a monetary adjustment that reduces the price paid or dollar amount received by an entity engaging in a prescription drug transaction that occurs during the prescription drug transaction as reflected on the invoice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(24)">(24)</span> “Disease burden” means the impact of a health condition measured by financial cost, mortality, morbidity, severity, and epidemiological indicators.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(25)">(25)</span> “Drug class” means the grouping of medications based on a common active ingredient, or ingredients, or by pharmacologic or therapeutic class.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(26)">(26)</span> “Drug-specific patient access program” means a program designed to provide a patient with assistance in affording a prescription drug or paying for a prescription drug, including but not limited to the provision of a drug to a patient, coupons supplied by the manufacturer, donations to a nonprofit or foundation associated with the manufacturer, and donations to an independent nonprofit that are earmarked expressly for the manufacturer’s drugs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(27)">(27)</span> “Federal Supply Schedule (FSS)” means the drug pricing program under the collection of multiple award contracts used by federal agencies, U.S. territories, Indian tribes, and other specified entities to purchase supplies and services from outside vendors.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(28)">(28)</span> “Food and Drug Administration (FDA)” means the federal agency of the U.S. Department of Health and Human Services tasked with protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, medical devices, and certain other consumer products.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(29)">(29)</span> “Formulary” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gin&amp;section=15-1601" title="">Insurance Article, §15-1601, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(30)">(30)</span> “Fund” means the Prescription Drug Affordability Fund, as provided for in Health-General Article, §21-2C-11, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(31)">(31)</span> “Generic drug” has the meaning stated in Health-General Article, §21-2C-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(32)">(32)</span> “Gross spending” means the sum of all monies paid for a prescription drug product for an individual patient in a calendar year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(33)">(33)</span> “Health economics and outcomes research” means the form of economic analysis that compares the relative costs and outcomes of different treatments, such as cost effectiveness analysis, comparative effectiveness research, health economic information analysis, and health technology assessments.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(34)">(34)</span> “Health maintenance organization (HMO)” has the meaning stated in Health-General Article, §19-701, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(35)">(35)</span> “Indication” means labeling that discusses the disease or condition the drug product is intended to diagnose, treat, prevent, cure, or mitigate, including a description of the patient population.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(36)">(36)</span> “Insurance benefit design” means the rules that determine the services covered by the plan and any other cost-sharing measures.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(37)">(37)</span> “Managed care organization (MCO)” has the meaning stated in Health-General Article, §15-102.4, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(38)">(38)</span> “Manufacturer” has the meaning stated in Health-General Article, §21-2C-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(39)">(39)</span> “Maryland Medical Care Database (MCDB)” means the database established and maintained by the Maryland Health Care Commission pursuant to Health-General Article, §19-133, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(40)">(40)</span> “Medicaid” means the public health program jointly administered by the federal government and states that primarily serves low-income people (children, parents, and, in certain states, other adults) and some medically needy patients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(41)">(41)</span> “Medicare” means the health insurance program administered by the federal government for people 65 years old or older or with certain disabilities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(42)">(42)</span> “National average drug acquisition cost (NADAC)” means the pricing benchmark calculated from the Centers for Medicare &amp; Medicaid Services’ (CMS) monthly surveys of retail pharmacies that reflects the average price pharmacies pay to acquire a drug from a wholesaler or manufacturer, excluding subsequent discounts or rebates from manufacturers to wholesalers or pharmacies.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(43)">(43)</span> “National Drug Code (NDC)” means the unique three-segment number used for identification and reporting as set forth in 21 CFR §207.33.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(44)">(44)</span> “Net cost” means the per-unit cost paid by payors and purchasers of a drug after accounting for all price concessions, discounts, and rebates.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(45)">(45)</span> “Net price” means the per-unit amount received by manufacturers of a drug after accounting for price concessions, discounts, and rebates.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(46)">(46)</span> “New drug application (NDA)” means a submission to the FDA for the review and potential approval for marketing of a drug product, which includes chemical, pharmacological, medical, biopharmaceutical, and statistical data, as defined in 21 CFR §314.3 and described under 21 CFR §314.50.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(47)">(47)</span> “Other cost-sharing” means a program, benefit design, or other mechanism that determines a patient’s responsibility for a prescription drug product, such as a copayment, coinsurance, deductible, formulary, or other management tool.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(48)">(48)</span> “Out-of-pocket costs” means the expenses for medical care, including prescription drug therapy, that are not reimbursed by insurance and are paid by a patient, including copayments, coinsurance, and deductibles for covered services, and the costs for all non-covered services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(49)">(49)</span> “Patient total out-of-pocket costs” means the sum of a patient’s out-of-pocket costs, including items such as copayments, coinsurance, and deductibles, in a calendar year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(50)">(50)</span> “Payor” means the entity other than the patient that is responsible for paying for health care costs, including health insurance carriers, health plan sponsors, PBMs, Medicare, Medicaid, MCOs, and HMOs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(51)">(51)</span> “Person” means an individual, limited liability company, partnership, corporation, association, county, and public or private organization of any character other than an agency.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(52)">(52)</span> “Pharmacy benefit manager (PBM)” means a third-party administrator of prescription drug programs as stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gin&amp;section=15-1601" title="">Insurance Article, §15-1601, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(53)">(53)</span> “Prescription drug product” has the meaning stated in Health-General Article, §21-2C-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(54)">(54)</span> “Price concession” means a mechanism other than a rebate or discount that reduces the price paid by a payor.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(55)">(55)</span> “Proprietary” means something that is used, produced, or marketed under the exclusive legal right of the inventor, maker, or owner.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(56)">(56)</span> “Purchaser” means an entity that purchases prescription drug products that is not a payor or patient.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(57)">(57)</span> “Rebate” means a monetary adjustment that reduces the price paid or dollar amount received by an entity engaging in a prescription drug transaction that occurs after the prescription drug transaction.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(58)">(58)</span> “Regulatory exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by the FDA with respect to a pharmaceutical product other than patents, including but not limited to 180-day exclusivity, orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, and pediatric exclusivity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(59)">(59)</span> “Stakeholder Council” means the Prescription Drug Affordability Stakeholder Council, as provided for in Health-General Article, §21-2C-04, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(60)">(60)</span> “Standard medical practice” means the customary treatment by medical professionals:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(60)(a)">(a)</span> Based on credible scientific evidence published in peer reviewed medical literature generally recognized by the relevant medical community;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(60)(b)">(b)</span> Consistent with physician specialty society recommendations; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(60)(c)">(c)</span> Consistent with the views of physicians practicing in the relevant clinical areas.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(61)">(61)</span> “State actual acquisition cost (SAAC)” has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01#B(42)" title="">COMAR 10.09.03.01B(42)</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(62)">(62)</span> “System net cost” means the sum of the net cost as defined above and the per unit patient out-of-pocket cost.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(63)">(63)</span> “Therapeutic alternative” means a drug product that has one or more of the same or similar indications for use as a particular drug but is not a therapeutic equivalent to that drug.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(64)">(64)</span> “Therapeutic class” means a group of drugs containing active moieties that share scientifically documented properties and are defined on the basis of any combination of three attributes: mechanism of action, physiologic effect, and chemical structure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(65)">(65)</span> “Therapeutic equivalent” has the meaning stated in 21 CFR §314.3.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(66)">(66)</span> “Total gross spending” means the sum of all monies paid for a prescription drug product in a calendar year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(67)">(67)</span> “Total patient out-of-pocket cost” means the sum of all patient out-of-pocket costs in a calendar year, including items such as copayments, coinsurance, and deductibles.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(68)">(68)</span> “Trade secret” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcl&amp;section=11-1201" title="">Commercial Law Article, §11-1201, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(69)">(69)</span> “Wholesale acquisition cost (WAC)” means the manufacturer’s list price for a prescription drug product to wholesalers or direct purchasers in the United States, not including prompt pay or other discounts, rebates, or reductions in price, as reported in a wholesale price guide or other publication of prescription drug product pricing data.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(70)">(70)</span> “Wholesale distributor” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-6" title="">Health Occupations Article, §12-6</a>C-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.01#B(71)">(71)</span> “Utilization” means information about the use of a drug including the number of units, the number of patients and number of prescriptions or claims.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.01.02" data-order="|14|01|01|.02|" data-ref-path="14|01|01|.02" class="h__section">.02 Rules of Construction.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#A">A.</span> Singular and Plural. In interpreting and applying this subtitle, the singular includes the plural.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B">B.</span> Computation of Time.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(1)">(1)</span> In computing a period of time prescribed by this subtitle or an applicable statute, after a day, act, or event occurs, the following rules apply:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(1)(a)">(a)</span> The day of the act, event, or default after which the designated period of time begins to run is not included;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(1)(b)">(b)</span> If the period of time allowed is more than 7 days, intermediate Saturdays, Sundays, and legal holidays are counted;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(1)(c)">(c)</span> If the period of time allowed is 7 days or less, intermediate Saturdays, Sundays, and legal holidays are not counted; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(1)(d)">(d)</span> The last day of the computed period is included unless it is a Saturday, Sunday, or legal holiday, in which event the period runs until the end of the next day that is a work day.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(2)">(2)</span> In computing a period of time prescribed by this subtitle or an applicable statute, before a day, act, or event occurs, the following rules apply:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(2)(a)">(a)</span> In determining the latest day for performing an act that is required to be performed a prescribed number of days before a certain day, act, or event, all days preceding that day, including intervening Saturdays, Sundays, and legal holidays, are counted in the number of days so prescribed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.02#B(2)(b)">(b)</span> The latest day is included in the determination unless it is a Saturday, Sunday, or legal holiday, in which event the latest day is the first preceding day that is a work day.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.01.03" data-order="|14|01|01|.03|" data-ref-path="14|01|01|.03" class="h__section">.03 Open Meetings.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#A">A.</span> Public Attendance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#A(1)">(1)</span> The general public is invited to attend and observe an open session of the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#A(2)">(2)</span> A member of the public attending an open session may not participate in the session, except when:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#A(2)(a)">(a)</span> The Board expressly invites public testimony, questions, comments, or other forms of public participation; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#A(2)(b)">(b)</span> Public participation is otherwise authorized by law or regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#A(3)">(3)</span> The Chair, or the Chair’s designee, may extend or waive any time requirement in this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#B">B.</span> Public Comments. A member of the public may provide oral public comment and written public comment in accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.01.05" title=".05 Public Comment Procedures.">Regulation .05 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#C">C.</span> Disruptive Conduct.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#C(1)">(1)</span> An individual attending an open session of the Board may not engage in any conduct, including visual demonstrations such as waving of placards, signs, or banners, that disrupts the session or that interferes with the right of members of the public to attend and observe the session.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#C(2)">(2)</span> Restoring Order. The presiding officer or Chair may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#C(2)(a)">(a)</span> Order an individual who persists in conduct prohibited by <a class="internal-link " href="/us/md/exec/comar/14.01.01.03#C(1)" title="">§C(1) of this regulation</a>, or who has violated any other regulation concerning the conduct of the open session, to be removed or disconnected from the session, and may request police assistance to restore order; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.03#C(2)(b)">(b)</span> Recess the session while order is restored.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.01.04" data-order="|14|01|01|.04|" data-ref-path="14|01|01|.04" class="h__section">.04 Confidential, Trade-Secret, and Proprietary Information.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A">A.</span> Collection of Records and Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)">(1)</span> Identification.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)(a)">(a)</span> A person submitting information, including data and records, for the Board’s consideration under this subtitle and Health-General Article, Title 21, Subtitle 2C, Annotated Code of Maryland, shall:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)(a)(i)">(i)</span> Clearly designate the specific information the person considers to be confidential, trade-secret, or proprietary; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)(a)(ii)">(ii)</span> Submit a form certifying that the information so designated is not otherwise publicly available and has been handled and maintained to preserve its confidential, trade-secret, or proprietary nature.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)(b)">(b)</span> The Board may also determine that information it has received is confidential, trade-secret, or proprietary.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)(c)">(c)</span> The Board may seek additional information regarding whether the information is confidential, trade-secret, proprietary, or not otherwise publicly available from:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)(c)(i)">(i)</span> The person submitting the information; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(1)(c)(ii)">(ii)</span> To the extent the Board is able to determine who created the document or information, the person who created the document or information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(2)">(2)</span> Designation. The information and data obtained by the Board under this subtitle and Health-General Article, Title 21, Subtitle 2C, Annotated Code of Maryland, that is not otherwise publicly available, is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(2)(a)">(a)</span> Considered to be a trade secret and confidential and proprietary information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#A(2)(b)">(b)</span> Is not subject to inspection or disclosure under the Public Information Act.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B">B.</span> Management of Information Received by the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(1)">(1)</span> Access to Information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(1)(a)">(a)</span> Confidential, trade-secret, or proprietary information obtained by the Board under this subtitle and Health-General Article, Title 21, Subtitle 2C, Annotated Code of Maryland, may be accessed only by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(1)(a)(i)">(i)</span> Board members; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(1)(a)(ii)">(ii)</span> Board staff including a qualified independent third party that has contracted with the Board and is subject to a nondisclosure agreement prohibiting disclosure of such information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(1)(b)">(b)</span> A person with access to confidential, trade-secret, or proprietary information shall maintain the confidentiality of the information in accordance with <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsg&amp;section=10-617" title="">State Government Article, §10-617, </a>and Health-General Article, §21-2C-10, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(2)">(2)</span> Consideration by Board.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(2)(a)">(a)</span> The Board may discuss confidential, trade-secret, and proprietary information in a closed session.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.04#B(2)(b)">(b)</span> The Board may not disclose confidential, trade-secret, or proprietary information in an open meeting, its public meeting materials, or its summary report of a cost review study.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.01.05" data-order="|14|01|01|.05|" data-ref-path="14|01|01|.05" class="h__section">.05 Public Comment Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A">A.</span> Public Oral Comments for a Board Meeting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A(1)">(1)</span> A member of the public may register to provide oral comments at a Board meeting by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A(1)(a)">(a)</span> Submitting a written notice that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A(1)(a)(i)">(i)</span> Contains the individual’s name and email address or phone number;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A(1)(a)(ii)">(ii)</span> Identifies whether the individual is affiliated with or commenting on behalf of an organization, agency, employer, or other entity; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A(1)(a)(iii)">(iii)</span> Identifies the agenda item the individual wishes to address; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A(1)(b)">(b)</span> Submitting the written notice to the Board at least 2 work days before the scheduled meeting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#A(2)">(2)</span> Oral comments shall be made to the Board in open session.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B">B.</span> Public Written Comment Procedures.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)">(1)</span> General Procedures.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(a)">(a)</span> Unless expressly exempted, these provisions apply to all written public comments.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(b)">(b)</span> Except as provided in <a class="internal-link " href="/us/md/exec/comar/14.01.01.05#B(5)" title="">§B(5) of this regulation</a>, a member of the public may submit written comments to the Board by email, courier, or postal service.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(c)">(c)</span> An individual submitting comments on behalf of an organization, agency, employer, or other entity shall:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(c)(i)">(i)</span> Submit the comments on the letterhead of the organization, agency, employer, or other entity; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(c)(ii)">(ii)</span> Disclose in writing the organization, agency, employer, or other entity with which the individual is affiliated;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(d)">(d)</span> Written comments received by the date prescribed by regulation or set by the Board will be:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(d)(i)">(i)</span> Shared with the Board;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(d)(ii)">(ii)</span> Where applicable, made part of the record on the issue or matter before the Board where applicable; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(d)(iii)">(iii)</span> Posted on the Board’s website.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(1)(e)">(e)</span> Board staff shall redact sociological information prior to posting the written comments on the Board website.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(2)">(2)</span> Public Written Comments for a Board Meeting.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(2)(a)">(a)</span> A member of the public may submit written comments concerning any agenda item of the Board or any decision pending before the Board in accordance with the procedures in §B(1) and (5) of this regulation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(2)(b)">(b)</span> Written comments received more than 2 work days before the scheduled Board meeting will be shared with the Board prior to the Board meeting.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(2)(c)">(c)</span> Written comments received less than 2 work days before the scheduled Board meeting will be shared with the Board and posted on the Board’s website after the scheduled meeting.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(2)(d)">(d)</span> Written comments received less than 2 work days before the scheduled Board meeting may be considered at the next Board meeting if the issue, matter, or decision is still pending.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(3)">(3)</span> Public Written Comments Authorized by Regulation.  If a regulation expressly provides for public written comment, a member of the public may submit written comments to the Board within the time period prescribed by regulation in accordance with the procedures in §B(1) and (5) of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(4)">(4)</span> Public Written Comments Requested by the Board. If the Board requests public comment by posting notice of the request and a due date on its website, a member of the public may submit written comments to the Board within the time period prescribed by the notice in accordance with the procedures in §B(1) and (5) this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(5)">(5)</span> Public Written Comments Containing Confidential, Trade-Secret, and Proprietary Information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(5)(a)">(a)</span> A member of the public that wishes to submit written comments or attachments to written comments that contain confidential, trade-secret, and proprietary information shall:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(5)(a)(i)">(i)</span> Redact the specific information the person considers to be confidential, trade-secret, or proprietary from the written comments and attachments;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(5)(a)(ii)">(ii)</span> Submit a form certifying that the redacted information is not otherwise publicly available and has been handled and maintained to preserve its confidential, trade-secret, or proprietary nature;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(5)(a)(iii)">(iii)</span> Submit the redacted comments and attachments to the Board by email, courier, or postal service; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(5)(a)(iv)">(iv)</span> Submit the unredacted comments and attachments to the Board in paper form using a tracked common carrier, courier, or postal service, or electronically using secure file transfer.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.05#B(5)(b)">(b)</span> The Board and Board staff shall use, protect, and manage written comments and attachments containing confidential, trade-secret, and proprietary information in compliance with <a class="internal-link " href="/us/md/exec/comar/14.01.01.04" title=".04 Confidential, Trade-Secret, and Proprietary Information.">Regulation .04 of this chapter</a> and Health-General Article, §§21-2C-03 and 21-2C-10, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.01.06" data-order="|14|01|01|.06|" data-ref-path="14|01|01|.06" class="h__section">.06 Hearing Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A">A.</span> Scope.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A(1)">(1)</span> This regulation applies to hearings held:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A(1)(a)">(a)</span> To gather information from the general public before making recommendations or taking action with respect to a policy; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A(1)(b)">(b)</span> For the purpose of receiving technical input, technical information or expert testimony before making recommendations or taking action with respect to a policy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A(2)">(2)</span> This regulation does not apply to contested case hearings, any part of an appeal process or a hearing where the purpose is other than to gather information from:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A(2)(a)">(a)</span> The public;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A(2)(b)">(b)</span> A person with a specific interest in the issue including a stakeholder; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#A(2)(c)">(c)</span> A person with specific knowledge, skills, expertise or technical information or input.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B">B.</span> General Hearing Provisions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)">(1)</span> Notice of Hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)(a)">(a)</span> The Board shall publish a notice of the hearing on the Board’s website.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)(b)">(b)</span> The Board shall include in the notice of the hearing:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)(b)(i)">(i)</span> The date and time of the hearing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)(b)(ii)">(ii)</span> The physical location of the hearing, or link or registration information if the hearing is held remotely or live streamed;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)(b)(iii)">(iii)</span> The purpose of the hearing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)(b)(iv)">(iv)</span> A statement that the Board will make reasonable accommodation for individuals with disabilities if these individuals advise the Board of their special needs by giving the Board reasonable advance notice; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(1)(b)(v)">(v)</span> Any other applicable information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)">(2)</span> Conducting a Quasi-Legislative Hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(a)">(a)</span> A hearing held under this regulation is quasi-legislative and may be conducted or presided over by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(a)(i)">(i)</span> The Board Chair; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(a)(ii)">(ii)</span> Designee.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(b)">(b)</span> The Chair or designee shall determine the conduct of the hearing, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(b)(i)">(i)</span> The order of presentation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(b)(ii)">(ii)</span> Time limits for questions and testimony.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(c)">(c)</span> The Chair or designee may:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(c)(i)">(i)</span> Order a person who engages in disruptive behavior that interferes with the orderly conduct of the hearing to be removed from the hearing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(c)(ii)">(ii)</span> Request police assistance to assure or restore order; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(c)(iii)">(iii)</span> Recess a disorderly hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(d)">(d)</span> For hearings held under this regulation the following does not apply:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(d)(i)">(i)</span> The right of cross-examination; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(d)(ii)">(ii)</span> The rules of evidence.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(e)">(e)</span> If an exhibit is offered and is relevant to the hearing, the Chair or designee shall receive and mark the exhibit offered in testimony.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(f)">(f)</span> Unless the Chair or designee believes that an oath provides some assurance of veracity, formality, or decorum to the hearing, the Chair or designee may dispense with the formality of an oath.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(g)">(g)</span> The Chair or designee has discretion to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(g)(i)">(i)</span> Postpone or continue the hearing; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#B(2)(g)(ii)">(ii)</span> Accept additional materials beyond the date of the hearing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C">C.</span> Informational Hearings.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(1)">(1)</span> Convening an Informational Hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(1)(a)">(a)</span> The Board may, through Board staff, convene informational hearings to receive input, information, and opinions from the public and stakeholders to inform the consideration and development of a recommendation, policy, regulation or action.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(1)(b)">(b)</span> The Board shall provide public notice of the hearing in accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.01.06#B" title="">§B of this regulation</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(1)(c)">(c)</span> In advance of the scheduled hearing, the Board may identify and publish questions, topics or matters about which the Board would like to receive information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)">(2)</span> Conducting an Informational Hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(a)">(a)</span> A person who wishes to provide input, information and opinions by testifying shall:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(a)(i)">(i)</span> Register to speak in advance of the hearing as directed by staff; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(a)(ii)">(ii)</span> Provide the information requested by staff.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(b)">(b)</span> The Chair or designee shall give all persons who register to speak an opportunity to do so but may limit repetitious testimony.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(c)">(c)</span> The Chair or designee may:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(c)(i)">(i)</span> Allow questions from the audience;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(c)(ii)">(ii)</span> Take questions from the audience and redirect the questions to others present at the hearing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(c)(iii)">(iii)</span> Ask questions of anyone present at the hearing; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(c)(iv)">(iv)</span> Refer questions to Board staff who may respond after the hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#C(2)(d)">(d)</span> Following an informational hearing, Board staff may provide the Board with summaries of the information received and staff’s recommendations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D">D.</span> Technical Hearings.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(1)">(1)</span> Convening a Technical Hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(1)(a)">(a)</span> The Board may convene a hearing for the purpose of receiving technical input, technical information or expert testimony from persons with specific knowledge, skills or expertise.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(1)(b)">(b)</span> The Board shall provide public notice of the hearing in accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.01.06#B" title="">§B of this regulation</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(1)(c)">(c)</span> The Board shall identify and invite a person to testify at a technical hearing to provide technical input, technical information or expert testimony on an issue the Board wishes to explore.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(1)(d)">(d)</span> The Board may request that a person invited to testify submit a written statement to the Board two business days before the scheduled hearing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(2)">(2)</span> Conducting a Technical Hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(2)(a)">(a)</span> The Chair may:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(2)(a)(i)">(i)</span> Ask questions of any person present at the hearing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(2)(a)(ii)">(ii)</span> Allow each Board member to ask questions of any person present at the hearing; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(2)(a)(iii)">(iii)</span> Refer questions to Board staff who may respond after the hearing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#D(2)(b)">(b)</span> Following a technical hearing, Board staff may provide the Board with summaries of the information received and staff’s recommendations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E">E.</span> Recordings of Quasi-Legislative Hearings.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E(1)">(1)</span> At the Board’s discretion, the Board or court reporter service may record the hearing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E(2)">(2)</span> If a court reporter service records the hearing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E(2)(a)">(a)</span> The Board shall arrange for the court reporter service to retain the recording for 1 year following the final decision or action; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E(2)(b)">(b)</span> A person who desires a copy of the transcript may purchase a copy from the court reporter service.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E(3)">(3)</span> If Board staff records the hearing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E(3)(a)">(a)</span> The Board shall keep the recording with the original of the record; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#E(3)(b)">(b)</span> A person who desires a copy of the transcript may purchase a copy from the Board for a reasonable cost in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.03" title="Chapter 03 Public Information Act">COMAR 14.01.03</a>, if a transcript has been prepared.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F">F.</span> Hearing Record.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(1)">(1)</span> The Chair or designee controls the record.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)">(2)</span> The Chair or designee shall assemble a record that may include the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(a)">(a)</span> Exhibits and documents entered into the record;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(b)">(b)</span> Documents concerning the hearing such as a proposed regulation, the purpose of the hearing and public notice of the hearing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(c)">(c)</span> Relevant supporting and opposing documentation obtained before, during, and subsequent to the hearing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(d)">(d)</span> The register of persons who attended the hearing including name, address, and any affiliation relevant to the hearing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(e)">(e)</span> In accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.01.06#E" title="">§E of this regulation</a>, any:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(e)(i)">(i)</span> Full or partial transcript of the hearing made or purchased by the Board, and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(e)(ii)">(ii)</span> A recording or stenographic notes of the hearing made by the Board; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(2)(f)">(f)</span> Board staff’s summaries of the information received and staff’s recommendations, if any.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.01.06#F(3)">(3)</span> The record of a policy action may include the hearing records of multiple hearings, public written comments, comments at Board meetings, Stakeholder Council input, any input, data, or information received and considered by the Board and any final action or decision.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/14.01.02" data-order="|14|01|02|" data-ref-path="14|01|02" class="h__chapter">Chapter 02 Prescription Drug Affordability Fund</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: September 6, 2021 (48:18 Md. R. 692)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.02.02" title=".02 Fee Assessment, Exemption, Waiver, and Collection.">Regulation .02</a> amended as an emergency provision effective November 16, 2021 (48:26 Md. R. 1107); emergency provision expired May 6, 2022</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.02.02" title=".02 Fee Assessment, Exemption, Waiver, and Collection.">Regulation .02</a> amended effective August 22, 2022 (49:17 Md. R. 791); October 2, 2023 (50:19 Md. R 854)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.02.03" title=".03 Amount of Assessment.">Regulation .03</a> amended effective August 19, 2024 (51:16 Md. R. 743)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.02.03#A" title="">Regulation .03A</a> amended effective October 2, 2023 (50:19 Md. R 854)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.02.03#B" title="">Regulation .03B</a> amended as an emergency provision effective November 16, 2021 (48:26 Md. R. 1107); emergency provision expired May 6, 2022</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.02.03#B" title="">Regulation .03B</a> amended effective August 22, 2022 (49:17 Md. R. 791)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§21-2C-03(f) and 21-2C-11, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/14.01.02.01" data-order="|14|01|02|.01|" data-ref-path="14|01|02|.01" class="h__section">.01 Prescription Drug Affordability Fund.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.01#A">A.</span> The Prescription Drug Affordability Fund is a special, non-lapsing fund that is not subject to State Procurement Article, §7–302, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.01#B">B.</span> The Prescription Drug Affordability Fund consists of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.01#B(1)">(1)</span> The assessment provided for by <a class="internal-link " href="/us/md/exec/comar/14.01.02.02" title=".02 Fee Assessment, Exemption, Waiver, and Collection.">Regulation .02 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.01#B(2)">(2)</span> Money appropriated by the State budget;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.01#B(3)">(3)</span> Interest earnings; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.01#B(4)">(4)</span> Any other money from any other source accepted for the benefit of the Fund.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.02.02" data-order="|14|01|02|.02|" data-ref-path="14|01|02|.02" class="h__section">.02 Fee Assessment, Exemption, Waiver, and Collection.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#A">A.</span> Annual Assessment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#A(1)">(1)</span> In each State fiscal year, the Board shall issue a fee assessment to each entity identified in Health-General Article, §21-2C-11, Annotated Code of Maryland, and <a class="internal-link " href="/us/md/exec/comar/14.01.02.03" title=".03 Amount of Assessment.">Regulation .03 of this chapter</a> and collect the assessment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#A(2)">(2)</span> Unless the entity requests and is granted an exemption from the assessment, the entity shall pay the assessment by October 1.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#A(3)">(3)</span> An entity may pay the assessment by ACH transfer, wire transfer, or check.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B">B.</span> Exemption from Assessment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(1)">(1)</span> An entity may request an exemption from the annual assessment by submitting a completed exemption form to the Board within 30 days of the Board transmitting the fee assessment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(2)">(2)</span> The exemption form shall be executed under oath and attest that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(2)(a)">(a)</span> The entity is not a qualifying entity as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01" title="Chapter 01 General Provisions">COMAR 14.01.01</a> and Health-General Article, §21-2C-11(b)(1), Annotated Code of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(2)(b)">(b)</span> The entity no longer does business in Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(2)(c)">(c)</span> The entity is not subject to assessment for another reason with an explanation of that reason.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(3)">(3)</span> The entity bears the burden of demonstrating it qualifies for the claimed exemption and shall submit documentation in support of the exemption request,  as follows:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(3)(a)">(a)</span> The entity shall provide an executed certificate of business record (available on the Board’s website) authenticating any business record the entity submits in support of the request for exemption.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(3)(b)">(b)</span> For carriers, supporting documentation may include but is not limited to NAIC “Annual Statement” including the cover page (signature page/jurat), Maryland State page, and Schedule T, acknowledgment from Maryland Insurance Administration of merger/change in subsidiary status, and SEC 10-K (any applicable exhibits).</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(3)(c)">(c)</span> For manufacturers, distributors, and PBMs, supporting documentation may include but is not limited to discharge in bankruptcy, documentation of merger/change in corporate structure/subsidiary status (for example, SEC 10-K and any applicable exhibits), acknowledgment from Board of Pharmacy of expiration of license/registration, expired license/registration, documentation that manufacturer/distributor provides only non-covered products (for example, provides gases only, product or inventory lists), and documentation that the entity does not do business in Maryland.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(3)(d)">(d)</span> If the entity is unable to provide any documentation supporting the claimed exemption, the entity shall provide an affidavit (form on Board’s website) from the chief operating officer, chief financial officer, or other authorized official attesting to the factual basis of the claimed exemption.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(4)">(4)</span> While the exemption request is pending, payment of the assessment is deferred.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#B(5)">(5)</span> The Board shall determine all requests for exemption promptly.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#C">C.</span> Reconsideration.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#C(1)">(1)</span> Within 15 days of the notice denying the exemption, an entity may file for reconsideration of the denial of a request for exemption by submitting:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#C(1)(a)">(a)</span> A request for reconsideration on the form provided; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#C(1)(b)">(b)</span> Additional information or documentation in support of the claimed exemption.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#C(2)">(2)</span> A request for reconsideration that does not include additional information or additional documentation will be denied.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#C(3)">(3)</span> If the request for exemption is denied after reconsideration, the entity shall pay the assessment within 30 days of the issuance of the notice of denial.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#D">D.</span> Collection and Penalties.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#D(1)">(1)</span> Any fee assessment not paid within 30 days of the payment due date may be subject to an interest penalty to be determined and collected by the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#D(2)">(2)</span> In addition to any penalties the Board may impose on an entity that fails to pay the fee assessed by the Board in a timely manner, the Board may also refer an entity’s delinquent account to the Department of Budget and Management’s Central Collection Unit, pursuant to the procedures in <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gsf/gsf.pdf" title="">State Finance and Procurement Article, Title 3, Subtitle 3, Annotated Code of Maryland</a>, and <a class="internal-link no-wrap" href="/us/md/exec/comar/17.01.01" title="Chapter 01 Standards for Administrative Collection of Claims">COMAR 17.01.01</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E">E.</span> Maintenance of Assessment List.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E(1)">(1)</span> The Board shall maintain a list of entities that are subject to assessment as identified in Health-General Article, §21-2C-11, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E(2)">(2)</span> At any time, Board staff may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E(2)(a)">(a)</span> Review the list, but staff shall review the list on at least an annual basis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E(2)(b)">(b)</span> Add additional entities reported by or obtained from other agencies or identified by staff; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E(2)(c)">(c)</span> Remove entities if the entity:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E(2)(c)(i)">(i)</span> Is no longer a going concern; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.02.02#E(2)(c)(ii)">(ii)</span> Has been determined to be exempt from assessment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.02.03" data-order="|14|01|02|.03|" data-ref-path="14|01|02|.03" class="h__section">.03 Amount of Assessment.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.03#A">A.</span> Entities identified in Health-General Article, §212C11, Annotated Code of Maryland, shall be subject to the following fee schedule:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.03#A(1)">(1)</span> Manufacturers engaged in wholesale distribution, as defined in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=126C" title="">Health Occupations Article, §126C</a>01, Annotated Code of Maryland, shall pay an assessment of $1,000;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.03#A(2)">(2)</span> Wholesale distributors, as defined in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=126C" title="">Health Occupations Article, §126C</a>01, Annotated Code of Maryland, that distribute prescription drugs shall pay an assessment of $1,000;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.03#A(3)">(3)</span> Pharmacy benefits managers, as defined in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gin&amp;section=151601" title="">Insurance Article, §151601, Annotated Code of Maryland</a>, shall pay an assessment of $1,000; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.02.03#A(4)">(4)</span> Carriers that provide health benefit plans, as defined in Health-General Article, §19-132(e), Annotated Code of Maryland, shall pay an assessment of $1,000.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.03#B">B.</span> An entity may request to pay the annual assessment in installments by submitting a letter to the Board demonstrating significant financial hardship in paying the assessment in a single payment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.02.04" data-order="|14|01|02|.04|" data-ref-path="14|01|02|.04" class="h__section">.04 Use of Funds.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.04#A">A.</span> The Fund may only be used to finance the operation of the Board, as permitted in Health-General Article, §21–2C–11(c)(6), Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.04#B">B.</span> Interest earned from the monies collected through the assessment in <a class="internal-link " href="/us/md/exec/comar/14.01.02.02" title=".02 Fee Assessment, Exemption, Waiver, and Collection.">Regulation .02 of this chapter</a> shall be retained to the credit of the Fund.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.02.05" data-order="|14|01|02|.05|" data-ref-path="14|01|02|.05" class="h__section">.05 Surplus Funds.</h3>
                <p>If the amount of assessed funds collected in a calendar year exceeds the cap identified in Health-General Article, §21–2C–11(B)(4), the Board shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.05#A">A.</span> Issue a notice of such surplus; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.02.05#B">B.</span> Remit the surplus funds in a fair and equitable manner across all qualifying entities that have paid the assessment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/14.01.03" data-order="|14|01|03|" data-ref-path="14|01|03" class="h__chapter">Chapter 03 Public Information Act</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: October 2, 2023 (50:19 Md. R. 854)</p>
                  <h3>Authority</h3>
                  <p>General Provisions Article §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-101" title="">4-101</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-601" title="">4-601</a>; Health-General Article, §21-2C-03(f)(1), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/14.01.03.01" data-order="|14|01|03|.01|" data-ref-path="14|01|03|.01" class="h__section">.01 Scope.</h3>
                <p>This chapter sets out procedures under the Public Information Act for filing and processing requests for the public records of the Prescription Drug Affordability Board.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.02" data-order="|14|01|03|.02|" data-ref-path="14|01|03|.02" class="h__section">.02 Policy.</h3>
                <p>It is the policy of the Board to facilitate access to the public records of the Board, if access is allowed by law, by minimizing costs and time delays to applicants.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.03" data-order="|14|01|03|.03|" data-ref-path="14|01|03|.03" class="h__section">.03 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(1)">(1)</span> “Act” means the Public Information Act, General Provisions Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-101" title="">4-101</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-601" title="">4-601</a>, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(2)">(2)</span> “Applicant” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-101" title="">General Provisions Article, §4-101(b), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(3)">(3)</span> “Copy” means any form of reproduction using a photocopying machine or other reproduction technology, including a paper copy, an electronic copy, a printout, or an image.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(4)">(4)</span> “Custodian” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-101" title="">General Provisions Article, §4-101(d), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(5)">(5)</span> “Executive Director” means the Executive Director of the Board as provided in Health-General Article, §21-2C-03, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(6)">(6)</span> “Indigent” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-206" title="">General Provisions Article, §4-206(a)(2), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(7)">(7)</span> “Metadata” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-205" title="">General Provisions Article, §4-205(a), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(8)">(8)</span> “Official custodian” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-101" title="">General Provisions Article, §4-101(f), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(9)">(9)</span> “PIA coordinator” means the Board employee who is responsible for accepting requests for public records.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(10)">(10)</span> “Public Access Ombudsman” means the official appointed under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/ggp/ggp.pdf" title="">General Provisions Article, Title 4, Subtitle 1B, Annotated Code of Maryland</a>, to resolve disputes under the Act.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(11)">(11)</span> “Public record” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-101" title="">General Provisions Article, §4-101(j), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(12)">(12)</span> “Reasonable fee” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-206" title="">General Provisions Article, §4-206(a)(3), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.03#B(13)">(13)</span> “Sociological information” means personal phone number, personal email address, and personal home address.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.04" data-order="|14|01|03|.04|" data-ref-path="14|01|03|.04" class="h__section">.04 Official Custodian.</h3>
                <p>Unless otherwise provided by law, the Executive Director is the official custodian of the public records of the Board.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.05" data-order="|14|01|03|.05|" data-ref-path="14|01|03|.05" class="h__section">.05 Request for Public Records.</h3>
                <p>Any person may request to inspect or copy the public records of the Board.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.06" data-order="|14|01|03|.06|" data-ref-path="14|01|03|.06" class="h__section">.06 Written Request May Be Required.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.06#A">A.</span> Inspection.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.06#A(1)">(1)</span> Except as otherwise provided in this chapter, the custodian shall make public records of the Board available for inspection by an applicant without demanding a written request.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.06#A(2)">(2)</span> The custodian shall require a written request if the custodian reasonably believes that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.06#A(2)(a)">(a)</span> The Act or any other law may prevent the disclosure of the public record to the applicant; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.06#A(2)(b)">(b)</span> A written request will materially assist the Board in responding.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.06#B">B.</span> Copies. If the applicant requests one or more copies of any public record of the Board, the custodian may require a written request.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.07" data-order="|14|01|03|.07|" data-ref-path="14|01|03|.07" class="h__section">.07 Contents of Written Request.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.07#A">A.</span> A written request shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.07#A(1)">(1)</span> Contain the applicant’s contact information; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.07#A(2)">(2)</span> Reasonably identify, by brief description, the public record sought.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.07#B">B.</span> Written requests from the same requestor may be consolidated</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.08" data-order="|14|01|03|.08|" data-ref-path="14|01|03|.08" class="h__section">.08 Addressee.</h3>
                <p>A request to inspect or copy a public record of the Board shall be addressed to the custodian of the record or to the Board’s PIA coordinator as designated under <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-503" title="">General Provisions Article, §4-503, Annotated Code of Maryland</a>. If the custodian is unknown, the request may be addressed to “Executive Director” or “PIA Coordinator”.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.09" data-order="|14|01|03|.09|" data-ref-path="14|01|03|.09" class="h__section">.09 Response to Request.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A">A.</span> Grant of Request.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A(1)">(1)</span> If the custodian decides to grant a request for inspection, the custodian shall produce the public record for inspection:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A(1)(a)">(a)</span> Immediately; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A(1)(b)">(b)</span> Within a reasonable time period, not to exceed 30 days after the date of the request, if that period is needed to retrieve the public record and conduct any necessary review.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A(2)">(2)</span> If the custodian reasonably believes that it will take more than 10 working days to produce the public record, the custodian shall indicate in writing or by electronic mail within 10 working days after receipt of the request:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A(2)(a)">(a)</span> The amount of time that the custodian anticipates it will take to produce the public record;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A(2)(b)">(b)</span> An estimate of the range of fees that may be charged to comply with the request for public records; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#A(2)(c)">(c)</span> The reason why it will take more than 10 working days to produce the records.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#B">B.</span> Denial of Request. If the custodian decides to deny a request for inspection, the custodian shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#B(1)">(1)</span> Deny the request within 30 days after the request; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#B(2)">(2)</span> Notify the applicant of the denial.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#C">C.</span> If a request is denied, the custodian shall provide the applicant, at the time of the denial or within 10 working days, a written statement that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#C(1)">(1)</span> The reasons for the denial, including, for records denied under <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-343" title="">General Provisions Article, §4-343, Annotated Code of Maryland</a>, a brief explanation of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#C(1)(a)">(a)</span> Why the denial is necessary, that is, why disclosure of the public record would be contrary to the public interest; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#C(1)(b)">(b)</span> An explanation of why redacting information would not address the reasons for the denial;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#C(2)">(2)</span> The legal authority for the denial;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#C(3)">(3)</span> Without disclosing the protected information, a brief description of the undisclosed record or records that will enable the applicant to assess the applicability of the legal authority for the denial; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#C(4)">(4)</span> Notice of the remedies available for review of the denial.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#D">D.</span> If a requested public record is not in the custody or control of the person to whom application is made, that person shall, within 10 working days after receipt of the request:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#D(1)">(1)</span> Notify the applicant that the person does not have custody or control of the requested public record; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#D(2)">(2)</span> If the person knows, include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#D(2)(a)">(a)</span> The name of the custodian of the public record; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#D(2)(b)">(b)</span> The location or possible location of the public record.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.09#E">E.</span> Any time limit imposed by §§A—C of this regulation may be extended, with the consent of the applicant, for an additional period of up to 30 days.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.10" data-order="|14|01|03|.10|" data-ref-path="14|01|03|.10" class="h__section">.10 Notice to Person Potentially Affected by Disclosure.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.10#A">A.</span> Unless prohibited by law, the custodian may provide notice of a request for inspection or copying of any public record of the Board to any person who, in the judgment of the custodian, could be adversely affected by disclosure of that public record.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.10#B">B.</span> The custodian may consider the views of the potentially affected person before deciding whether to disclose the public record to an applicant.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.11" data-order="|14|01|03|.11|" data-ref-path="14|01|03|.11" class="h__section">.11 Electronic Records.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#A">A.</span> Except as provided in §§C and D of this regulation, the custodian shall provide an applicant with a copy of the public record in a searchable and analyzable electronic format if:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#A(1)">(1)</span> The public record is in a searchable and analyzable electronic format;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#A(2)">(2)</span> The applicant requests a copy of the public record in a searchable and analyzable electronic format; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#A(3)">(3)</span> The custodian is able to provide a copy of the public record, in whole or in part, in a searchable and analyzable electronic format that does not disclose information that is protected from disclosure under the Act.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#B">B.</span> The custodian shall provide a portion of the public record in a searchable and analyzable electronic format if:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#B(1)">(1)</span> Requested by the applicant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#B(2)">(2)</span> The custodian is able to do so by using the existing functions of the database or software program that contains the searchable and analyzable data.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#C">C.</span> The custodian is not required to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#C(1)">(1)</span> Create or reconstruct a public record in an electronic format if the public record is not available in an electronic format;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#C(2)">(2)</span> Release an electronic record in a format that would jeopardize or compromise the security or integrity of the original record or of any proprietary software in which the record is maintained; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#C(3)">(3)</span> Create, compile, or program a new public record.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#D">D.</span> The custodian may remove metadata from an electronic document before providing the electronic record to an applicant by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#D(1)">(1)</span> Using a software program or function; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.11#D(2)">(2)</span> Converting the electronic record into a different searchable and analyzable format.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.12" data-order="|14|01|03|.12|" data-ref-path="14|01|03|.12" class="h__section">.12 Public Record Destroyed or Lost.</h3>
                <p>If the person to whom application is made knows that a requested public record of the Board has been destroyed or lost, that person shall promptly:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.12#A">A.</span> Notify the applicant that the public record is not available; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.12#B">B.</span> Explain the reasons why the public record cannot be produced.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.13" data-order="|14|01|03|.13|" data-ref-path="14|01|03|.13" class="h__section">.13 Availability of Judicial and Administrative Review.</h3>
                <p>If the custodian denies a request to inspect or copy a public record of the Board, the applicant may file an action for judicial enforcement under <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-362" title="">General Provisions Article, §4-362, Annotated Code of Maryland</a>, without pursuing the remedies set forth in General Provisions Article, Subtitles 1A and 1B, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.14" data-order="|14|01|03|.14|" data-ref-path="14|01|03|.14" class="h__section">.14 Disclosure Against Public Interest.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.14#A">A.</span> Denial Pending Court Order.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.14#A(1)">(1)</span> If, in the opinion of the Executive Director, disclosure of a public record of the Board otherwise subject to disclosure under the Act would do substantial injury to the public interest, the Executive Director may temporarily deny the request to obtain a court order allowing nondisclosure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.14#A(2)">(2)</span> The temporary denial shall be in writing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.14#B">B.</span> Circuit Court Review.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.14#B(1)">(1)</span> Within 10 working days after the denial, the Executive Director shall apply to the appropriate circuit court for an order permitting continued denial or restriction of access.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.14#B(2)">(2)</span> Notice of the Executive Director’s complaint shall be served on the applicant in the manner provided for service of process by the Maryland Rules of Procedure</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.15" data-order="|14|01|03|.15|" data-ref-path="14|01|03|.15" class="h__section">.15 Fees.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#A">A.</span> Except as provided in §§B and C of this regulation, the fee schedule for copying and certifying copies of public records of the Board is as follows:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#A(1)">(1)</span> For each copy made by a standard printer or a photocopying machine within the Board, the fee is 25 cents per page;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#A(2)">(2)</span> For each copy made other than by a standard printer or a photocopying machine within the Board, the fee shall be based on the actual cost of reproduction; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#A(3)">(3)</span> For a public record certified as a true copy, an additional fee of $1 per page (or, if appropriate, per item) shall be charged.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#B">B.</span> Minimum Fee. A charge may not be made if the total fee is $1 or less.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#C">C.</span> If the fee for copies or certified copies of any public record of the Board is specifically set by a law other than the Act or this regulation, the custodian shall charge the prescribed fee.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#D">D.</span> If the custodian cannot copy a public record within the Board, the custodian shall make arrangements for the prompt reproduction of the record at public or private facilities outside the Board. The custodian shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#D(1)">(1)</span> Collect from the applicant a fee to cover the actual cost of reproduction; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#D(2)">(2)</span> Direct the applicant to pay the cost of reproduction directly to the facility making the copy.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#E">E.</span> Before copying a public record of the Board, the custodian shall estimate both the cost of reproduction and the search and preparation fee under <a class="internal-link " href="/us/md/exec/comar/14.01.03.15#F" title="">§F of this regulation</a> and either:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#E(1)">(1)</span> Obtain the agreement of the applicant to pay the cost; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#E(2)">(2)</span> Demand prepayment of all or a portion of the cost.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#F">F.</span> Search and Preparation Fee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#F(1)">(1)</span> Except as provided in <a class="internal-link " href="/us/md/exec/comar/14.01.03.15#G" title="">§G of this regulation</a>, the custodian may charge a reasonable fee for time that an official or employee of the Board spends to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#F(1)(a)">(a)</span> Search for requested public records;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#F(1)(b)">(b)</span> Review requested public records for potential disclosure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#F(1)(c)">(c)</span> Prepare public records for inspection and copying.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#F(2)">(2)</span> The custodian shall determine the fee under <a class="internal-link " href="/us/md/exec/comar/14.01.03.15#F(1)" title="">§F(1) of this regulation</a> by multiplying the employee’s salary, prorated to an hourly basis, by the actual time attributable to the search for, review of, and preparation of public records for inspection and copying.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#G">G.</span> The custodian may not charge a search or preparation fee under <a class="internal-link " href="/us/md/exec/comar/14.01.03.15#F" title="">§F of this regulation</a> for the first 2 hours needed to search for and prepare a public record for inspection.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#H">H.</span> Waiver or Reduction of Fee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#H(1)">(1)</span> The official custodian may waive or reduce any fee set under this regulation if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#H(1)(a)">(a)</span> The applicant requests a waiver; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#H(1)(b)">(b)</span> Either:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#H(1)(b)(i)">(i)</span> The custodian determines that the waiver or reduction is in the public interest; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#H(1)(b)(ii)">(ii)</span> The applicant is indigent and files an affidavit verifying the facts that support a claim of indigency.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#H(2)">(2)</span> In determining whether a fee waiver is in the public interest, the custodian shall consider, among other relevant factors, the ability of the applicant to pay the fee.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.15#I">I.</span> If the applicant requests that copies of a public record be mailed or delivered to the applicant or to a third party, the custodian may charge the applicant for the cost of postage or delivery.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.16" data-order="|14|01|03|.16|" data-ref-path="14|01|03|.16" class="h__section">.16 Time and Place of Inspection.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.16#A">A.</span> An applicant may inspect any public record of the Board that the applicant is entitled to inspect during the normal working hours of the Board.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.03.16#B">B.</span> The inspection shall occur where the public record is located unless the custodian, after taking into account the applicant's expressed wish, determines that another place is more suitable and convenient.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.03.17" data-order="|14|01|03|.17|" data-ref-path="14|01|03|.17" class="h__section">.17 Sociological Information.</h3>
                <p>Except for use in carrying out the custodian’s governmental functions or if disclosure is otherwise required by law, and in compliance with <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ggp&amp;section=4-330" title="">General Provisions Article, §4-330, Annotated Code of Maryland</a>, a custodian may not disclose under the Act, and shall deny a request for inspection or copying of, the part of a public record that contains sociological information relating to an individual.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/14.01.04" data-order="|14|01|04|" data-ref-path="14|01|04" class="h__chapter">Chapter 04 Cost Review Study Process</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 25, 2023 (50:25 Md. R. 1089)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04.05" title=".05 Cost Review Study.">Regulation .05</a> amended as an emergency provision effective November 14, 2024 (51:25 Md. R. 1140); adopted permanently effective March 3, 2025 (52:4 Md. R. 220)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§21-2C-03(f)(1), 21-2C-08(b), and  21-2C-09, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/14.01.04.01" data-order="|14|01|04|.01|" data-ref-path="14|01|04|.01" class="h__section">.01 Public Reporting of Drug Affordability Issues.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.01#A">A.</span> Individual members of the public may report their personal experience with a drug or drugs that have caused or are causing an affordability issue for the individual.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.01#B">B.</span> Individuals may report a drug:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.01#B(1)">(1)</span> By completing the form available on the Board’s website electronically; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.01#B(2)">(2)</span> By downloading or obtaining the form from the Board, completing the form, and submitting it to the Board.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.01#C">C.</span> Blank forms may be requested by contacting the Board by email or phone.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.04.02" data-order="|14|01|04|.02|" data-ref-path="14|01|04|.02" class="h__section">.02 Identifying Drugs Eligible for Cost Review.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#A">A.</span> The Board shall apply the metrics specified in Health-General Article, §21-2C-08(c), Annotated Code of Maryland, and this regulation to the following data sets to identify drugs eligible for selection for a cost review study:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#A(1)">(1)</span> The claims data in the MCDB;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#A(2)">(2)</span> Available subsets of claims data in the MCDB, such as the commercial market, Medicaid, and Medicare; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#A(3)">(3)</span> The data obtained from governmental and commercial databases, other databases, and other data sets as available.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#B">B.</span> The Board may identify the prescription drug products that meet these statutory metrics and regulatory criteria on at least an annual basis.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#C">C.</span> Data Management.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#C(1)">(1)</span> For any metric requiring adjustment for inflation, the adjustment for inflation shall be based on the Consumer Price Index for All Urban Consumers (CPI-U) as reported by the U.S. Bureau of Labor Statistics.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#C(2)">(2)</span> For any data-based metric, the Board may account for data errors and outliers.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D">D.</span> To the extent practicable, and in addition to the statutory metrics set forth in Health-General Article, §21-2C-08(c), Annotated Code of Maryland, the Board may consider the following additional metrics and criteria to identify prescription drug products eligible for selection for a cost review study:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)">(1)</span> Aggregated Spending and Pricing Data:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)(a)">(a)</span> The 100 prescription drug products with the highest total gross spending in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)(b)">(b)</span> The 100 prescription drug products with the highest total gross spending per patient in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)(c)">(c)</span> The 100 prescription drug products with the highest percent change increase in WAC over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)(d)">(d)</span> The 100 prescription drug products with the highest percent change increase in WAC over the most recent available 5-year period;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)(e)">(e)</span> The 100 prescription drug products with the highest dollar increase in WAC per year or course of treatment over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)(f)">(f)</span> The 100 prescription drug products with the highest dollar increase in WAC over the most recent available 5-year period; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(1)(g)">(g)</span> The 100 prescription drug products with the highest percent change increase in total gross spending;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(2)">(2)</span> Patient Out-of-Pocket Costs:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(2)(a)">(a)</span> The 100 prescription drug products with the highest total patient out-of-pocket costs in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(2)(b)">(b)</span> The 100 prescription drug products with the highest average patient total out-of-pocket costs in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(2)(c)">(c)</span> The 100 prescription drug products ranked at the 50th percentile for patient total out-of-pocket costs in the most recent available calendar year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(2)(d)">(d)</span> The 100 prescription drug products ranked at the 90th percentile for patient total out-of-pocket costs; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#D(3)">(3)</span> Any prescription drug product added by the Board to the list of prescription drug products eligible for cost review under this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#E">E.</span> At an open meeting, a Board member may propose one or more additional prescription drug products for inclusion on the list of drugs eligible for cost review by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#E(1)">(1)</span> Moving that the prescription drug product or products be added to the eligible list; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#E(2)">(2)</span> Identifying how the prescription drug product or products may create affordability challenges for the State health care system or patients.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.02#F">F.</span> After discussion at an open meeting, the Board may vote to add one or more prescription drug products to the list of drugs eligible for selection for a cost review study.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.04.03" data-order="|14|01|04|.03|" data-ref-path="14|01|04|.03" class="h__section">.03 Selecting Drugs for Cost Review.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#A">A.</span> Board staff may provide the Board with a dashboard containing the prescription drug products identified under the statutory metrics and regulatory criteria in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B">B.</span> To the extent practicable, Board staff may provide the following information for each prescription drug product in the dashboard:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(1)">(1)</span> FDA Approval:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(1)(a)">(a)</span> The date the FDA first approved the prescription drug product;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(1)(b)">(b)</span> If applicable, the date the last patent expired or will expire;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(1)(c)">(c)</span> Whether the prescription drug product was approved through an FDA accelerated approval pathway; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(1)(d)">(d)</span> Whether the prescription drug product is designated by the Secretary of the FDA, under 21 U.S.C. §360bb, as a drug for a rare disease or condition;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(2)">(2)</span> Therapeutic Class:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(2)(a)">(a)</span> The class of the prescription drug product as identified in a recognized classification system;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(2)(b)">(b)</span> Whether the prescription drug product is the only prescription drug product in its class;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(2)(c)">(c)</span> Any therapeutic equivalent prescription drug product identified by examination of the FDA Orange Book, FDA Purple Book, or other therapeutic equivalence databases; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(2)(d)">(d)</span> The availability and number of therapeutic equivalents for sale in the State;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)">(3)</span> Utilization, Spending and Price Data:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(a)">(a)</span> The patient count for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(b)">(b)</span> The total gross spending for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(c)">(c)</span> The total gross spending per patient for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(d)">(d)</span> The WAC on January 1 of the current calendar year, on January 1 of the previous calendar year, and at launch of the product;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(e)">(e)</span> The percent increase in WAC of the prescription drug product over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(f)">(f)</span> The percent increase in WAC of the prescription drug product over the most recent available 5-year period;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(g)">(g)</span> The dollar increase in WAC over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(h)">(h)</span> The dollar increase in WAC over the most recent available 5-year period;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(i)">(i)</span> The dollar increase in WAC per year or course of treatment over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(j)">(j)</span> The percent increase in overall total gross spending for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(k)">(k)</span> The estimated percentage of manufacturer national net sales to gross sales of a prescription drug product for the most recently reported year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(l)">(l)</span> The average payor cost per patient for the prescription drug product in the most recent available calendar year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(3)(m)">(m)</span> The average cost share for the prescription drug product;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(4)">(4)</span> Patient Out-of-Pocket:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(4)(a)">(a)</span> The total patient out-of-pocket cost for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(4)(b)">(b)</span> The average total out-of-pocket costs in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(4)(c)">(c)</span> Patient total out-of-pocket costs ranked at the 50th percentile in the most recent available calendar year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(4)(d)">(d)</span> Patient total out-of-pocket costs ranked at the 90th percentile in the most recent available calendar year;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(5)">(5)</span> Whether the prescription drug product is currently in active shortage status; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#B(6)">(6)</span> Whether the prescription drug product is currently subject to or has been subject to the Medicare Drug Price Negotiation Program, under the Inflation Reduction Act (IRA) (Public Law 117-169).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C">C.</span> Selecting Drugs for Referral to Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(1)">(1)</span> The Board may select one or more prescription drug products identified in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a> as eligible for cost review to refer to the Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(2)">(2)</span> Prior to a Board meeting, a Board member may request that a prescription drug product or products be placed on the Board’s meeting agenda for consideration for referral to the Stakeholder Council by submitting the proprietary drug name or nonproprietary name, as applicable, and NDC to the Board Chair in writing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(3)">(3)</span> The Board Chair may include the prescription drug product name and dose on the Board’s agenda.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(4)">(4)</span> The public may provide oral and written comments concerning the drugs proposed for referral to the Stakeholder Council and identified on the meeting agenda in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(5)">(5)</span> Notwithstanding the pre-meeting identification of drugs for consideration, the Board may consider any drug identified in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a> for referral to the Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(6)">(6)</span> At an open meeting, the Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(6)(a)">(a)</span> Consider the prescription drug products identified on the Board’s agenda and any eligible drug proposed for consideration by a Board member at the meeting; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#C(6)(b)">(b)</span> Select one or more prescription drug products by NDC to refer to the Stakeholder Council to receive input from the Stakeholder Council on the selection of prescription drug products for cost review.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#D">D.</span> In selecting one or more prescription drug products to refer to the Stakeholder Council, the Board may consider:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#D(1)">(1)</span> The prescription drug products identified under the statutory metrics and regulatory criteria in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#D(2)">(2)</span> The information provided under §B this regulation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#D(3)">(3)</span> The average cost share of the prescription drug product, the average patient total out-of-pocket cost, and the average total payor cost; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#D(4)">(4)</span> Any written or oral public comment.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#E">E.</span> The Board shall post notice of the prescription drug products referred to the Stakeholder Council on its website.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#F">F.</span> The public may provide written comments concerning the list of prescription drug products referred to the Stakeholder Council by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#F(1)">(1)</span> Complying with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(3)" title="">COMAR 14.01.01.05B(3)</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#F(2)">(2)</span> Submitting the written comments to the Board within 30 calendar days of the date the list is posted on the Board’s website.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G">G.</span> Stakeholder Council Input.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(1)">(1)</span> To the extent practicable, the Board may provide the Stakeholder Council with:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(1)(a)">(a)</span> The information set forth in <a class="internal-link " href="/us/md/exec/comar/14.01.04.03#B" title="">§B of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(1)(b)">(b)</span> Whether the prescription drug product was reported by an individual member of the public; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(1)(c)">(c)</span> Whether the prescription drug product was added by the Board for consideration under <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(2)">(2)</span> To the extent practicable, the Stakeholder Council shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(2)(a)">(a)</span> Review the information provided for each referred prescription drug product; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(2)(b)">(b)</span> Discuss the referred prescription drug products at an open meeting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#G(3)">(3)</span> Board staff may present the Stakeholder Council input discussed at the open meeting to the Board.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H">H.</span> Therapeutic Alternatives.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H(1)">(1)</span> Board staff may develop a list of therapeutic alternatives for each prescription drug product referred to the Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H(2)">(2)</span> Board staff shall post a list of therapeutic alternatives developed by staff on the Board’s website for comment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H(3)">(3)</span> The public may provide written comments concerning the list of therapeutic alternatives by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H(3)(a)">(a)</span> Complying with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(3)" title="">COMAR 14.01.01.05B(3)</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H(3)(b)">(b)</span> Submitting the written comments to the Board within 30 calendar days of the date the list is posted on the Board’s website.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H(4)">(4)</span> Board staff may modify the list of therapeutic alternatives for consideration by the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#H(5)">(5)</span> The Board shall determine the therapeutic alternatives for each prescription drug product selected for a cost review study.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I">I.</span> Board Selection of Drugs for Cost Review.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(1)">(1)</span> At an open meeting, the Board may select one or more prescription drug products for a cost review study.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(2)">(2)</span> The public may provide oral and written comments concerning the selection of a prescription drug product for cost review in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(3)">(3)</span> In selecting a prescription drug product for cost review, the Board shall consider:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(3)(a)">(a)</span> The prescription drug products referred to the Stakeholder Council from the prescription drug products identified under the statutory metrics and regulatory criteria in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a> and the information provided under <a class="internal-link " href="/us/md/exec/comar/14.01.04.03#B" title="">§B of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(3)(b)">(b)</span> The average cost share of the prescription drug product, the average patient total out-of-pocket cost, the average total payor cost, and publicly available data on direct-to-consumer advertising spending for the prescription drug product;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(3)(c)">(c)</span> Input from the Stakeholder Council provided under <a class="internal-link " href="/us/md/exec/comar/14.01.04.03#G" title="">§G of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(3)(d)">(d)</span> Input from the public provided under <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05" title=".05 Public Comment Procedures.">COMAR 14.01.01.05</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(4)">(4)</span> During an open meeting, the Board may select one or more prescription drug products for cost review under <a class="internal-link " href="/us/md/exec/comar/14.01.04.05" title=".05 Cost Review Study.">Regulation .05 of this chapter</a> and provide notice of the selection on its website within 3 work days of the meeting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(5)">(5)</span> The prescription drug product shall be identified by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(5)(a)">(a)</span> NDC;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(5)(b)">(b)</span> ANDA, NDA, or BLA, as applicable; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(5)(c)">(c)</span> Active moiety or active ingredient.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(6)">(6)</span> If the Board selects a prescription drug product for cost review, the Board may identify and approve all NDCs marketed under the same ANDA, NDA, or BLA to be included in the cost review.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(7)">(7)</span> If the Board selects a prescription drug product for cost review that is an unapproved generic within the meaning of Health-General Article, §21-2C-01(f), Annotated Code of Maryland, the Board may identify and approve all NDCs with the same active moiety and manufacturer to be included in the cost review study.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.03#I(8)">(8)</span> If the Board selects a prescription drug product for cost review, the Board shall approve the therapeutic alternatives to be used in conducting the cost review study.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.04.04" data-order="|14|01|04|.04|" data-ref-path="14|01|04|.04" class="h__section">.04 Request for Information for Cost Review.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A">A.</span> Request for Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(1)">(1)</span> The Board shall post notice of the prescription drug product or products selected for cost review through the process outlined in <a class="internal-link " href="/us/md/exec/comar/14.01.04.03#I" title="">Regulation .03I of this chapter</a> on the Board’s website.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(2)">(2)</span> To the extent there is no publicly available information to conduct an aspect of the statutory cost review, the Board may request information to conduct a cost review study under Health-General Article, §21-2C-09(a)(2), Annotated Code of Maryland, and this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(3)">(3)</span> The Board may request information by sending an email or postal mail to the manufacturer, PBMs, health insurance carriers, wholesale distributors, HMOs, and MCOs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(4)">(4)</span> The Board shall post notice of the request for information on its website.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(5)">(5)</span> An entity that has not received a request for information from the Board may submit relevant information in accordance with this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(6)">(6)</span> Within 30 days of the date the request for information is posted to the website or transmitted to the entity, an entity may submit the information requested by the Board, and any other relevant information, in accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.04.04#C" title="">§C of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(7)">(7)</span> An entity may request one 30-day extension of time to submit information under <a class="internal-link " href="/us/md/exec/comar/14.01.04.04#A(6)" title="">§A(6) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#A(8)">(8)</span> An entity shall submit the request for a 30-day extension to the Board in writing on or before the expiration of the initial submission period.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B">B.</span> For each prescription drug product under review, the Board may request the following information from:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)">(1)</span> Manufacturer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(a)">(a)</span> Documents and research explaining the relationship between the pricing of the prescription drug product and the cost of development, the relationship between the pricing of the prescription drug product and the therapeutic benefit, and information that is otherwise pertinent to the manufacturer’s pricing decision such as:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(a)(i)">(i)</span> Life cycle management;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(a)(ii)">(ii)</span> Net average price in the State; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(a)(iii)">(iii)</span> The estimated value or cost-effectiveness of the prescription drug product;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(b)">(b)</span> The total amount of the price concessions, discounts, and rebates provided to each payor type operating in the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(c)">(c)</span> The total amount of the price concessions, discounts, and rebates the manufacturer is expected to provide to each payor type;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(d)">(d)</span> The net price received by manufacturers for the drug product in the State accounting for all price concessions, discounts, and rebates;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(e)">(e)</span> The units of the prescription drug product sold in the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(f)">(f)</span> The units of the prescription drug product sold nationally;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(g)">(g)</span> The total dollar amount of sales of the prescription drug product into the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(h)">(h)</span> The total dollar amount of sales of the prescription drug product nationally;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(i)">(i)</span> The invoice price per unit for the prescription drug product charged to purchasers in the United Kingdom, Germany, France, and Canada, reported in U.S. dollars;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(j)">(j)</span> Prices charged to purchasers in the State, including but not limited to pharmacies, pharmacy chains, pharmacy wholesalers, and other direct purchasers;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(k)">(k)</span> The average profit margin of the prescription drug product over the prior 5-year period and the projected profit margin anticipated for the current year for the prescription drug product;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(l)">(l)</span> Maryland and national gross and net manufacturer revenues for the prescription drug product under review for the most recent tax year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(m)">(m)</span> Information concerning all authorized generics as defined by 42 CFR §447.502 for the prescription drug product;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(n)">(n)</span> Information concerning all other ANDAs, BLAs, and NDAs that pertain to the same active moiety and the same manufacturer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(o)">(o)</span> The manufacturer’s research and development costs, as indicated on the manufacturer’s federal tax filing or information filed with the Federal Securities and Exchange Commission for the most recent tax year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(p)">(p)</span> The portion of direct-to-consumer marketing costs eligible for favorable federal tax treatment in the most recent tax year that are specific to the prescription drug product under review; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(1)(q)">(q)</span> Any additional factors or information the manufacturer proposes that the Board consider.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(2)">(2)</span> Health Insurance Carrier, HMO, and MCO:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(2)(a)">(a)</span> The total amount of the price concessions, discounts, and rebates the manufacturer provides to each health plan operating in the State, expressed as a percent of the WAC;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(2)(b)">(b)</span> The average price concession, discount, and rebate provided in the State for therapeutic alternatives;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(2)(c)">(c)</span> Placement in each formulary offered or administered in the State and the number of covered lives for each formulary;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(2)(d)">(d)</span> Benefit design around the prescription drug product, including copayment and coinsurance amounts in the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(2)(e)">(e)</span> The net cost incurred by the insurance carrier for the prescription drug product in the State; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(2)(f)">(f)</span> Any additional factors or information the health insurance carrier, HMO, or MCO proposes that the Board consider.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)">(3)</span> Pharmacy Benefits Managers:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)(a)">(a)</span> The therapeutic alternatives for the prescription drug product(s) under review identified by each formulary administered by the PBM;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)(b)">(b)</span> The total amount of the price concessions, discounts, and rebates the manufacturer provides to each PBM operating in the State, expressed as a percent of the WAC;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)(c)">(c)</span> The average price concession, discount, and rebate provided in the State for therapeutic alternatives;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)(d)">(d)</span> Placement in each formulary offered or administered in the State and the number of covered lives for each formulary;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)(e)">(e)</span> Benefit design around the prescription drug product, including copayment and coinsurance amounts;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)(f)">(f)</span> Maryland and national gross and net PBM revenues for the prescription drug product under review for the most recent tax year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(3)(g)">(g)</span> Any additional factors or information the PBM proposes that the Board consider.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(4)">(4)</span> Wholesale Distributors:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(4)(a)">(a)</span> Prices charged to purchasers in the State, including but not limited to pharmacies, pharmacy chains, pharmacy wholesalers, and other direct purchasers;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(4)(b)">(b)</span> The total amount of price concessions and discounts provided by the wholesale distributor to purchasers in the State, including but not limited to pharmacies, pharmacy chains, pharmacy wholesalers, and other direct purchasers;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(4)(c)">(c)</span> Units of the prescription drug product sold in the State; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#B(4)(d)">(d)</span> Any additional factors or information the wholesale distributor proposes that the Board consider.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C">C.</span> Submission of Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C(1)">(1)</span> An entity may submit the information requested in <a class="internal-link " href="/us/md/exec/comar/14.01.04.04#A" title="">§A of this regulation</a> by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C(1)(a)">(a)</span> Completing the data form developed by the Board; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C(1)(b)">(b)</span> Providing supporting documentation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C(2)">(2)</span> A person submitting information, including data and records, for the Board’s consideration shall comply with the procedures for designating confidential, trade-secret, and proprietary information set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.04" title=".04 Confidential, Trade-Secret, and Proprietary Information.">COMAR 14.01.01.04</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C(3)">(3)</span> Information may be submitted to the Board:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C(3)(a)">(a)</span> In paper form using a tracked common carrier, courier, or postal service; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.04#C(3)(b)">(b)</span> Electronically using secure file transfer.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.04.05" data-order="|14|01|04|.05|" data-ref-path="14|01|04|.05" class="h__section">.05 Cost Review Study.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A">A.</span> The Board may determine:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A(1)">(1)</span> Whether use of the prescription drug product has led or will lead to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A(1)(a)">(a)</span> Affordability challenges to the State health care system; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A(1)(b)">(b)</span> High out-of-pocket costs for patients;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A(2)">(2)</span> Whether the use that has led to affordability challenges or high out-of-pocket costs is consistent with:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A(2)(a)">(a)</span> The labeling approved by the FDA; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A(2)(b)">(b)</span> Standard medical practice; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#A(3)">(3)</span> The circumstances under which the prescription drug product has or will lead to an affordability challenge to the State health care system or high out-of-pocket costs to patients under <a class="internal-link " href="/us/md/exec/comar/14.01.04.05#A(1)" title="">§A(1) of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B">B.</span> Analyses and Data Compilation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(1)">(1)</span> To the extent practicable, Board staff may assemble the data and analyses specified by Health-General Article §21-2C-09(b), Annotated Code of Maryland, and this regulation for consideration by the Board, including the data elements and information provided to the Board under Regulation .03A and B of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)">(2)</span> These data and analyses may be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(a)">(a)</span> Derived from published peer-reviewed literature;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(b)">(b)</span> Derived from published public sources such as the FDA Orange Book, the FDA Purple Book, and other sources;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(c)">(c)</span> Reported by or derived from manufacturers, health insurance plans, HMOs, MCOs, PBMs, and wholesale distributors;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(d)">(d)</span> Produced by Board staff through analysis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(e)">(e)</span> Derived from external analyses and modeling studies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(f)">(f)</span> Derived from the MCDB, any claims set of the MCDB, and any other databases containing relevant information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(g)">(g)</span> Derived from reports generated by U.S. governmental entities, State governmental entities, foreign governmental and quasi-governmental agencies, and U.S. and foreign non-profit organizations; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#B(2)(h)">(h)</span> Derived from quantitative and qualitative data collected by Board staff.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C">C.</span> Factors Considered in Cost Review Study.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)">(1)</span> To the extent practicable, the Board may consider the following data, information, and analyses in conducting a cost review study:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(a)">(a)</span> Drug Pricing for Drug Product Under Review:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(a)(i)">(i)</span> The WAC, AWP, NADAC, SAAC, ASP, and FSS; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(a)(ii)">(ii)</span> Information estimating manufacturer net price and net sales amounts of the prescription drug product under review;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(b)">(b)</span> Price Concessions, Discounts, and Rebates:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(b)(i)">(i)</span> The average price concession, discount, and rebate provided by the manufacturer or expected to be provided to each payor class in the State for the drug under review, expressed as a number and as a percent of the WAC; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(b)(ii)">(ii)</span> The average price concession, discount, and rebate the manufacturer provided or is expected to provide for the prescription drug product under review to each PBM operating in the State, expressed as a number and as a percent of the WAC;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(c)">(c)</span> Therapeutic Alternatives:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(c)(i)">(i)</span> The average price concession, discount, or rebate the manufacturer provides or is expected to provide to health plans in the State for therapeutic alternatives;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(c)(ii)">(ii)</span> The WAC, AWP, NADAC, SAAC, ASP, and FSS at which each therapeutic alternative has been sold in the State; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(c)(iii)">(iii)</span> The utilization, costs, and out-of-pocket costs for therapeutic alternatives;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(d)">(d)</span> Patient Access:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(d)(i)">(i)</span> The costs to health plans based on patient access consistent with FDA-labeled indications or standard medical practice;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(d)(ii)">(ii)</span> The estimated impact on patient access resulting from the cost of the prescription drug product relative to insurance benefit design; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(d)(iii)">(iii)</span> The current or expected dollar value of drug-specific patient access programs that are supported by the manufacturer for the drug product under review and the policies surrounding and implementing such programs;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(e)">(e)</span> Cost and Comparative Effectiveness Analyses:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(e)(i)">(i)</span> The incremental costs associated with a prescription drug product, including financial impacts to health, medical, or social services as can be quantified and compared to baseline effects of existing therapeutic alternatives; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(e)(ii)">(ii)</span> Information derived from health economics and outcomes research that may address the effectiveness of the prescription drug product in treating the conditions for which it is prescribed or in improving a patient’s health, quality of life, or overall health outcomes, and the effectiveness of the prescription drug product compared with therapeutic alternatives or no treatment.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(f)">(f)</span> Cost Sharing:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(f)(i)">(i)</span> The average patient copay and other cost-sharing data for the prescription drug in the State; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(f)(ii)">(ii)</span> The average cost share; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)">(g)</span> Additional Board Factors:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(i)">(i)</span> Clinical information, including FDA indications and doses and information concerning standard medical practice;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(ii)">(ii)</span> The disease burden of the condition that is treated by the prescription drug product;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(iii)">(iii)</span> In the case of generic prescription drug products, the number of pharmaceutical manufacturers that produce the prescription drug product;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(iv)">(iv)</span> The total gross spending in the State for the prescription drug product under review, the total number of patients in the State using the prescription drug product, and the percentage of overall total prescription drug product spending that the product’s spending represents;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(v)">(v)</span> The change in total gross spending and utilization for a prescription drug product in the State between the two most recent available calendar years and the percent change in total gross spending for a prescription drug product in the State between the two most recent available calendar years;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(vi)">(vi)</span> The mean, median, and 90th percentile out-of-pocket costs per patient compared to State incomes;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(vii)">(vii)</span> An assessment of the impact of the prescription drug product’s cost to access by priority populations and the impact on equity;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(viii)">(viii)</span> Information supplied by the manufacturer, if any, explaining the relationship between the pricing of the prescription drug product and (a) the cost of development and (b) the therapeutic benefit of the prescription drug product, or information that is otherwise pertinent to the manufacturer’s pricing decision;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(ix)">(ix)</span> Analysis of the prescription drug product’s approval process;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(x)">(x)</span> Analysis of the prescription drug product’s shortage status;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xi)">(xi)</span> Analysis of the market context of the prescription drug product including the prescription drug product’s lifecycle management, patent management, regulatory exclusivities, and product hopping;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xii)">(xii)</span> The utilization and pricing of therapeutically equivalent drug products;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xiii)">(xiii)</span> Analysis of the impact of state and federal regulatory and compliance issues related to the prescription drug product;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xiv)">(xiv)</span> Input from state and local governmental entities and the entities’ contractors such as health plans and plan administrators;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xv)">(xv)</span> Impact of the utilization and spending for the prescription drug product on public budgets and comparison of the spending on the prescription drug product to relevant benchmarks;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xvi)">(xvi)</span> Analyses and research including literature review by Board staff in response to information submitted by an entity under <a class="internal-link " href="/us/md/exec/comar/14.01.04.04" title=".04 Request for Information for Cost Review.">Regulation .04 of this chapter</a>, or through any public comment or public input procedure</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xvii)">(xvii)</span> Input from the public; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(1)(g)(xviii)">(xviii)</span> Information and analyses submitted by an entity under <a class="internal-link " href="/us/md/exec/comar/14.01.04.04" title=".04 Request for Information for Cost Review.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(2)">(2)</span> The public may provide written comments concerning the prescription drug product:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(2)(a)">(a)</span> Within 60 days of the date the drug’s selection for cost review study is posted on the Board’s website; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#C(2)(b)">(b)</span> In accordance with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(3)" title="">COMAR 14.01.01.05B(3)</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D">D.</span> At an open meeting, the Board may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(1)">(1)</span> Hear oral public comments concerning the prescription drug product in accordance with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(2)">(2)</span> To the extent permitted by Health-General Article, §§21-2C-03 and 21-2C-10, Annotated Code of Maryland, consider written comments submitted in accordance with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05" title=".05 Public Comment Procedures.">COMAR 14.01.01.05</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(3)">(3)</span> To the extent practicable, and in compliance with Health-General Article, §21-2C-03(e)(1)(iv), Annotated Code of Maryland, consider the data and analyses specified by <a class="internal-link " href="/us/md/exec/comar/14.01.04.05#C" title="">§C of this regulation</a>, including the data elements and information provided to the Board under <a class="internal-link " href="/us/md/exec/comar/14.01.04.03" title=".03 Selecting Drugs for Cost Review.">Regulation .03 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(4)">(4)</span> Close the session to discuss confidential, trade-secret, and proprietary information; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(5)">(5)</span> Preliminarily determine whether:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(5)(a)">(a)</span> Use of the prescription drug product, identified by NDC, has led or will lead to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(5)(a)(i)">(i)</span> Affordability challenges to the State health care system; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(5)(a)(ii)">(ii)</span> High out-of-pocket costs for patients; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(5)(b)">(b)</span> Whether the use that has led to affordability challenges or high out-of-pocket costs is consistent with:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(5)(b)(i)">(i)</span> The labeling approved by the FDA; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#D(5)(b)(ii)">(ii)</span> Standard medical practice.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#E">E.</span> If the Board is unable to determine whether a prescription drug product will produce or has produced challenges to the affordability of the prescription drug product for the State health care system, the Board may consider:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#E(1)">(1)</span> The additional factors identified in Health-General Article, §21-2C-09(b)(3)(i)—(iv), Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#E(2)">(2)</span> The following additional factors:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#E(2)(a)">(a)</span> Federal support for the research and development of the prescription drug product; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#E(2)(b)">(b)</span> Pricing data from other countries for the prescription drug product.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#F">F.</span> Preliminary Determination.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#F(1)">(1)</span> In accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.04.05#C" title="">§C of this regulation</a>, the Board may make a preliminary determination of whether use of the prescription drug product has led or will lead to affordability challenges for the State health care system or high out-of-pocket costs for patients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#F(2)">(2)</span> A preliminary determination is non-final and subject to revision and modification.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#F(3)">(3)</span> Preliminary Determination of Affordability Challenge.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#F(3)(a)">(a)</span> Board staff shall prepare a draft of the preliminary determination cost review report that summarizes the information considered by the Board in conducting the cost review study, the Board’s deliberations, the circumstances or indicia reflecting the affordability challenge, and the Board’s preliminary determination.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#F(3)(b)">(b)</span> The public may comment on the draft of the preliminary determination cost review report.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#G">G.</span> Final Determination Concerning Affordability Challenge and Final Cost Review Study Report.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#G(1)">(1)</span> The Board may vote to finalize the preliminary determination and approve the draft cost review report as final.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#G(2)">(2)</span> The Board’s determination of whether a prescription drug has or will lead to an affordability challenge is not final until the final cost review report is adopted by the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.04.05#G(3)">(3)</span> The Board shall create and adopt a final report of the cost review study that, to the extent permitted by Health-General Article, §§21-2C-03 and 21-2C-10, Annotated Code of Maryland, summarizes the information considered by the Board in conducting the cost review study, the Board’s deliberations, and the Board’s determination.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/14.01.05" data-order="|14|01|05|" data-ref-path="14|01|05" class="h__chapter">Chapter 05 Consumer Regulations</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: April 28, 2025 (52:8 Md. R. 359)</p>
                </section>
                <h3 id="/us/md/exec/comar/14.01.05.01" data-order="|14|01|05|.01|" data-ref-path="14|01|05|.01" class="h__section">.01 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(1)">(1)</span> “Driver” means a factor that causes a particular phenomenon to happen or develop.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(2)">(2)</span> “Eligible governmental entity” means a unit of State or local government, an organization on behalf of a unit of State or local government, or the Maryland State Medical Assistance Program, as identified in Health-General Article, §21-2C-14(a), Annotated Code of Maryland, that pays for or purchases prescription drug products.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(3)">(3)</span> “Eligible governmental entities upper payment limit” or “GovUPL” means upper payment limit established by the Board minus applicable patient out-of-pocket costs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(4)">(4)</span> “FDA prescription drug shortage list” means the U.S. Food and Drug Administration’s Drug Shortage Database.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(5)">(5)</span> “Medicaid Best Price” has the meaning stated in 42 CFR §447.505.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(6)">(6)</span> “Medicare Maximum Fair Price” has the meaning stated in 42 USC §1320f(c)(3).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(7)">(7)</span> “System net ingredient cost” means the final system cost attributable to or related to the prescription drug product after accounting for all discounts and price concessions, excluding dispensing, administration and direct and indirect remuneration to pharmacies, including patient out-of-pocket costs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#B(8)">(8)</span> “Upper payment limit” or “UPL” means the amount established by the Board and represents the system net ingredient cost.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.01#C">C.</span> For the purpose of this chapter, “affordability challenge” refers to either (a) high out-of-pocket costs for patients or (b) an affordability challenge for the State health care system.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.02" data-order="|14|01|05|.02|" data-ref-path="14|01|05|.02" class="h__section">.02 Criteria for Setting an Upper Payment Limit.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#A">A.</span> When determining whether to set an upper payment limit and when setting an upper payment limit amount, the Board shall apply the criteria set forth in this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#B">B.</span> The Board shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#B(1)">(1)</span> Consider the cost of administering the drug and delivering the drug to consumers, as well as other relevant administrative costs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#B(2)">(2)</span> Determine whether an upper payment limit is an appropriate tool to address the drivers of the affordability challenge identified for the prescription drug product;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#B(3)">(3)</span> Set an upper payment limit in a way to minimize adverse outcomes and minimize the risk of unintended consequences; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#B(4)">(4)</span> Prioritize drugs that have a high proportion of out-of-pocket costs compared to the system net cost of the drug.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#C">C.</span> The Board shall not set an upper payment limit if:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#C(1)">(1)</span> Spending on the prescription drug product by the eligible governmental entities is less than the administrative cost to implement an upper payment limit; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#C(2)">(2)</span> The prescription drug product is a generic and there are nine or more marketed therapeutic equivalents for the product.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#D">D.</span> The Board shall not set an upper payment limit at an amount that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#D(1)">(1)</span> Impacts statutory or regulatory amounts, such as Medicaid Best Price; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.02#D(2)">(2)</span> Is lower than the Medicare Maximum Fair Price.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.03" data-order="|14|01|05|.03|" data-ref-path="14|01|05|.03" class="h__section">.03 Policy Review and Final Action Process Overview.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#A">A.</span> If the Board makes a preliminary determination that use of the prescription drug product has led or will lead to an affordability challenge, the Board shall commence the policy review process.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#B">B.</span> The purpose of the policy review process is to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#B(1)">(1)</span> Based on the best available information, confirm the drivers and market conditions causing the affordability challenge phenomena; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#B(2)">(2)</span> Identify the policies that may address those drivers and redress the affordability challenges.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C">C.</span> The policy review process includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(1)">(1)</span> Information gathering:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(1)(a)">(a)</span> Informational hearings;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(1)(b)">(b)</span> Stakeholder Council input;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(1)(c)">(c)</span> Expert testimony hearings;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(1)(d)">(d)</span> Board staff research and analysis; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(1)(e)">(e)</span> Eligible governmental entities’ information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(2)">(2)</span> Preliminary policy recommendations:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(2)(a)">(a)</span> Policy actions other than UPLs; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(2)(b)">(b)</span> Policy action in the form of a UPL and the process for setting upper payment limits; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(3)">(3)</span> Final actions:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(3)(a)">(a)</span> Adoption of the final cost review report;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(3)(b)">(b)</span> Adoption of non-UPL policy recommendations; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.03#C(3)(c)">(c)</span> Adoption of proposed regulations setting a UPL amount.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.04" data-order="|14|01|05|.04|" data-ref-path="14|01|05|.04" class="h__section">.04 Policy Review—Information Gathering.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#A">A.</span> In studying the drivers, market conditions and policy options, the Board and staff may consider the information collected through the cost review study process pursuant to Health-General Article, §21-2C-09, Annotated Code of Maryland and <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04.05" title=".05 Cost Review Study.">COMAR 14.01.04.05</a>, including all information, analyses, and public input collected and considered during the selection of drug for the cost review study and the cost review study process.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#B">B.</span> If additional information is needed, the Board and staff may gather additional information through the tools outlined in <a class="internal-link " href="/us/md/exec/comar/14.01.05.04#D" title="">§D of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#C">C.</span> If additional information is needed, the Board may utilize the information-gathering tools outlined in <a class="internal-link " href="/us/md/exec/comar/14.01.05.04#D" title="">§D of this regulation</a> at any point in the policy review process, including the consideration and setting of a UPL.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D">D.</span> Information Gathering Tools.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(1)">(1)</span> Public Informational Hearings.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(1)(a)">(a)</span> The Board may, through Board staff, convene a hearing to receive input, information, and opinions from the public and stakeholders to inform the consideration and development of policy options including upper payment limits to redress an affordability challenge.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(1)(b)">(b)</span> The public informational hearing shall be conducted in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.06" title=".06 Hearing Procedures.">COMAR 14.01.01.06</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(2)">(2)</span> Stakeholder Council Input.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(2)(a)">(a)</span> The Board may request input from the Stakeholder Council. This input can be a request for general input and ideas on policies or more specific requests for specific information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(2)(b)">(b)</span> Board staff may provide the Board with summaries of input from the Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(3)">(3)</span> Technical Hearings.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(3)(a)">(a)</span> The Board may convene a hearing for the purpose of receiving technical input, technical information or expert testimony.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(3)(b)">(b)</span> The technical hearing shall be conducted in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.06" title=".06 Hearing Procedures.">COMAR 14.01.01.06</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(4)">(4)</span> Board Staff Research and Analysis.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(4)(a)">(a)</span> Board staff may provide the Board with policy research and analyses related to the drivers of the potential affordability and potential options.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(4)(b)">(b)</span> Research may include a literature review of available literature and original quantitative or qualitative research conducted by staff.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(5)">(5)</span> Eligible Governmental Entities’ Information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(5)(a)">(a)</span> Board staff may collect information concerning the prescription drug product and therapeutic alternatives from eligible governmental entities.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.04#D(5)(b)">(b)</span> The information collected may include utilization, spending, costs, benefit design, formulary placement, rebates, discounts, price concessions and other relevant information.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.05" data-order="|14|01|05|.05|" data-ref-path="14|01|05|.05" class="h__section">.05 Policy Review—Preliminary Policy Recommendations.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#A">A.</span> When developing preliminary policy recommendations for the Board, Board staff may use information gathered or obtained through the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#A(1)">(1)</span> Cost review study process under <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04" title="Chapter 04 Cost Review Study Process">COMAR 14.01.04</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#A(2)">(2)</span> Information gathering process under <a class="internal-link " href="/us/md/exec/comar/14.01.05.04" title=".04 Policy Review—Information Gathering.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B">B.</span> Policy Action Other than UPL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(1)">(1)</span> Board staff may recommend policy options to redress the affordability challenge.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(2)">(2)</span> When recommending policy options, Board staff may analyze the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(2)(a)">(a)</span> Drivers of the affordability challenge;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(2)(b)">(b)</span> How the policy addresses a driver;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(2)(c)">(c)</span> Strengths and weaknesses of the policy;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(2)(d)">(d)</span> Possible implementation of the policy through legislation, regulation, or enforcement; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(2)(e)">(e)</span> Potential impacts of the policy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(3)">(3)</span> The Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(3)(a)">(a)</span> Adopt none of the non-UPL policy recommendations;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(3)(b)">(b)</span> Adopt one or more policy recommendations; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(3)(c)">(c)</span> Adopt and modify one or more policy recommendations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(4)">(4)</span> The Board may adopt a final policy recommendation only after the Board has:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(4)(a)">(a)</span> Made a final affordability challenge determination; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(4)(b)">(b)</span> Adopted the final cost review study report under <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04.05#G" title="">COMAR 14.01.04.05G</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#B(5)">(5)</span> The public may provide oral and written comments concerning any agenda item of the Board or any decision pending before the Board in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C">C.</span> Policy Action in the Form of an Upper Payment Limit.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(1)">(1)</span> Board staff may recommend a UPL as a policy option to redress an affordability challenge.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)">(2)</span> When recommending a UPL as a policy option, Board staff may analyze the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)(a)">(a)</span> The drivers and market conditions causing the affordability challenge phenomena;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)(b)">(b)</span> Ability of a UPL to address these issues;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)(c)">(c)</span> Strengths and weaknesses of the UPL policy;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)(d)">(d)</span> Potential impacts of the UPL policy;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)(e)">(e)</span> Possible implementation of the policy through legislation, regulation or enforcement;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)(f)">(f)</span> Relevant regulatory criteria under <a class="internal-link " href="/us/md/exec/comar/14.01.05.02" title=".02 Criteria for Setting an Upper Payment Limit.">Regulation .02 of this chapter</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(2)(g)">(g)</span> Use of the drug by eligible governmental entities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(3)">(3)</span> Board staff may provide recommendations related to establishing a UPL including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(3)(a)">(a)</span> An assessment of the drivers of the affordability challenge; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(3)(b)">(b)</span> The extent to which a UPL may address the drivers.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(4)">(4)</span> The Board may pursue development of a UPL as a policy option and direct Board staff to provide recommendations concerning the frameworks and contextual information that may be used to set a UPL in accordance with the UPL process set forth in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06" title=".06 Policy Review—Process for Establishing a UPL.">Regulation .06 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.05#C(5)">(5)</span> The public may provide oral and written comments concerning any agenda item of the Board or any decision pending before the Board in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.06" data-order="|14|01|05|.06|" data-ref-path="14|01|05|.06" class="h__section">.06 Policy Review—Process for Establishing a UPL.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A">A.</span> Staff Recommends Frameworks and Contextual Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A(1)">(1)</span> Board staff shall recommend at least one framework, identified in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#B" title="">§B of this regulation</a>, for use in developing a UPL for the subject prescription drug product.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A(2)">(2)</span> Board staff may recommend certain contextual information identified in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#C" title="">§C of this regulation</a> for use in developing a UPL for the subject prescription drug product.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A(3)">(3)</span> Board staff shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A(3)(a)">(a)</span> Post staff’s recommendations on the Board’s website in advance of the Board meeting; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A(3)(b)">(b)</span> Request public comment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A(4)">(4)</span> The public may submit written comments by the date specified in the posting in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(4)" title="">COMAR 14.01.01.05B(4)</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#A(5)">(5)</span> Board staff shall present the recommendations to the Board.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B">B.</span> Frameworks.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(1)">(1)</span> Cost Effectiveness Analysis.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(1)(a)">(a)</span> Under this framework, a maximum UPL value may be set by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(1)(a)(i)">(i)</span> Using a cost-effectiveness analysis to model how much additional health outcome is gained per dollar of additional spending when using a drug product compared to an alternative;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(1)(a)(ii)">(ii)</span> Comparing this number to a threshold to determine if a product is “cost-effective”; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(1)(a)(iii)">(iii)</span> Then, if the product is not already cost-effective, given the specified threshold in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#B(1)(a)(ii)" title="">§B(1)(a)(ii) of this regulation</a> and the model in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#B(1)(a)(i)" title="">§B(1)(a)(i) of this regulation</a>, calculating the maximum UPL for which it would be “cost-effective.”</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(1)(b)">(b)</span> When providing a UPL amount developed using this framework, Board staff shall identify the health outcome, threshold, and relevant underlying assumptions used in the analysis.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(2)">(2)</span> Therapeutic Class Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(2)(a)">(a)</span> Under this framework, a UPL value may be set using the lowest net price or net cost among competitor products in the same therapeutic class.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(2)(b)">(b)</span> The Board may limit the prescription drug products used for analysis to a subset of drugs in the same therapeutic class.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(2)(c)">(c)</span> When determining whether to use a product in the same therapeutic class as a reference product, the Board may consider:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(2)(c)(i)">(i)</span> A difference in indication including a difference in the patient population and disease severity; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(2)(c)(ii)">(ii)</span> Comparative effectiveness research.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(3)">(3)</span> Launch Price-Based Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(3)(a)">(a)</span> Under this framework, a UPL value may be set based on the initial price at which the drug was first marketed (launch price) adjusted for inflation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(3)(b)">(b)</span> The Board shall adjust the launch price using the CPI-U.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)">(4)</span> Same Molecule Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(a)">(a)</span> Under the same molecule reference UPL framework, a UPL value may be set by comparing prices of certain reference drugs:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(a)(i)">(i)</span> A generic drug product that is therapeutically equivalent to the product under the review;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(a)(ii)">(ii)</span> An authorized generic of the product under review;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(a)(iii)">(iii)</span> A drug product licensed under a BLA that has the same active ingredient and is approved for one or more of the same or similar indications as the product under review;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(a)(iv)">(iv)</span> A biosimilar for the product under review;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(a)(v)">(v)</span> The reference product for the product under review; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(a)(vi)">(vi)</span> A drug product approved under an NDA or ANDA that has the same active ingredient and is approved for one or more of the same or similar indications as the product under review.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(b)">(b)</span> When using this framework Board staff may consider:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(b)(i)">(i)</span> Any differences between the product under review and the same molecule reference products; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(4)(b)(ii)">(ii)</span> The utilization of the same molecule reference products.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(5)">(5)</span> Domestic Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(5)(a)">(a)</span> Under the domestic reference UPL framework, a UPL value may be set using the estimated net cost of a prescription drug product to other purchasers and payors for the same prescription drug product within the United States or the net price received by the manufacturer.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(5)(b)">(b)</span> Under this framework, the UPL may be set using the cost of the lowest estimated net-cost purchaser or payor, excluding Medicaid.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(5)(c)">(c)</span> The Board may consider information for all other payors, including information on the Medicare Maximum Fair Price.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(6)">(6)</span> International Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(6)(a)">(a)</span> Under the international reference UPL framework, a UPL value may be set by comparing drug prices in other countries.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(6)(b)">(b)</span> Under this framework, the Board may consider the lowest price received by manufacturers for sales in the United Kingdom, Germany, France, and Canada, converted to U.S. dollars.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(7)">(7)</span> Budget Impact-Based Upper Payment Limits.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(7)(a)">(a)</span> Under the budget impact-based UPL framework, a UPL value may be set so that spending on the drug does not exceed a certain percentage of a budget as specified by the Board or have a disproportionate impact on that budget.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(7)(b)">(b)</span> The Board may consider current spending, projected spending, and potential offsets in developing a UPL value.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(7)(c)">(c)</span> When setting the percentage, the Board may consider the number of patients impacted, the disease burden, the current and projected future spending on other treatments and management of the disease.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(8)">(8)</span> Blend of Multiple Frameworks.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(8)(a)">(a)</span> Under this framework, Board staff may recommend potential UPL values derived from:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(8)(a)(i)">(i)</span> A blend of frameworks; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(8)(a)(ii)">(ii)</span> A variation in implementing a framework.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#B(8)(b)">(b)</span> When providing a blended UPL amount developed using this framework, Board staff shall identify how the potential blended UPL value was generated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C">C.</span> Contextual Information for the Prescription Drug Product:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(1)">(1)</span> Information gathered during the cost review study process or the policy review process;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(2)">(2)</span> Net costs for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(2)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(2)(b)">(b)</span> County, bicounty, and municipal health plans;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(2)(c)">(c)</span> Direct government purchases; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(2)(d)">(d)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(3)">(3)</span> Total out-of-pocket costs in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(3)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(3)(b)">(b)</span> County, bicounty, and municipal health plans; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(3)(c)">(c)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(4)">(4)</span> Current coverage status of the drug in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(4)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(4)(b)">(b)</span> County, bicounty, and municipal health plans; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(4)(c)">(c)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(5)">(5)</span> Utilization in the following program by patients and prescriptions:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(5)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(5)(b)">(b)</span> County, bicounty, and municipal health plans; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(5)(c)">(c)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(6)">(6)</span> Amount of direct government purchases by units and patients served;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(7)">(7)</span> For the Maryland State Medical Assistance Program:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(7)(a)">(a)</span> Number of prescriptions paid;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(7)(b)">(b)</span> Number of patients who received the prescription drug product; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(7)(c)">(c)</span> Total amount paid for the prescription drug product;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(8)">(8)</span> Budget impact analysis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(9)">(9)</span> Comparisons of health system costs to research and development costs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(10)">(10)</span> Life cycle revenue analysis; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#C(11)">(11)</span> Information that can be derived from the aggregation, calculation, and comparison of available information.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D">D.</span> UPL Values.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(1)">(1)</span> The Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(1)(a)">(a)</span> Select one or more of the frameworks and contextual information identified in §§B and C of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(1)(b)">(b)</span> Identify another framework;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(1)(c)">(c)</span> Prioritize the selected and identified frameworks and contextual information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(1)(d)">(d)</span> Direct staff to use the selected and identified frameworks and contextual information to perform analyses and calculations to obtain UPL values.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(2)">(2)</span> Based on guidance from the Board and the regulatory criteria under <a class="internal-link " href="/us/md/exec/comar/14.01.05.02" title=".02 Criteria for Setting an Upper Payment Limit.">Regulation .02 of this chapter</a>, Board staff shall perform calculations and analyses to develop a collection of potential UPL values.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(3)">(3)</span> These calculations and analyses may include appropriate adjustments to ensure that the UPL value:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(3)(a)">(a)</span> Reflects all discounts, rebates and price concessions;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(3)(b)">(b)</span> Excludes dispensing and administration fees and direct and indirect renumeration to pharmacies; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(3)(c)">(c)</span> Includes patient out-of-pocket costs other than costs attributable to dispensing fees under <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#D(3)(b)" title="">§D(3)(b) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(4)">(4)</span> Board staff shall post a public version of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(4)(a)">(a)</span> The UPL values developed through analysis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(4)(b)">(b)</span> Staff’s recommendation for a proposed UPL amount with a description of the calculation and analyses and relevant underlying assumptions used in the analysis such as health outcome or threshold; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(4)(c)">(c)</span> A request for public written comment on the Board’s website.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(5)">(5)</span> Board staff may also request public written comment addressing specific questions or proposing alternative analyses.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#D(6)">(6)</span> The public may submit written comments by the date specified in the posting in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(4)" title="">COMAR 14.01.01.05B(4)</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#E">E.</span> Technical Hearing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#E(1)">(1)</span> The Board may convene a hearing for the purpose of receiving technical input, technical information or expert testimony.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#E(2)">(2)</span> The technical hearing shall be conducted in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.06" title=".06 Hearing Procedures.">COMAR 14.01.01.06</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#F">F.</span> Amendment of Recommendations and UPL Values.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#F(1)">(1)</span> Board staff may modify or amend the public version of the developed UPL values, and staff’s recommendations for a proposed UPL amount.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#F(2)">(2)</span> If Board staff modifies or amends the developed UPL values and staff’s recommendations, staff shall post the amendments to the Board’s website, and request public written comment by a specified date.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.06#F(3)">(3)</span> The public may submit written comments by the date specified in the posting in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(4)" title="">COMAR 14.01.01.05B(4)</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.07" data-order="|14|01|05|.07|" data-ref-path="14|01|05|.07" class="h__section">.07 Policy Review—Final Policy Action.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#A">A.</span> Final Determination Concerning Affordability Challenge.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#A(1)">(1)</span> Prior to taking an action with respect to policy, the Board shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#A(1)(a)">(a)</span> Make a final determination of whether the prescription drug has or will create an affordability challenge; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#A(1)(b)">(b)</span> Adopt as final a cost review study report under <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04.05#G" title="">COMAR 14.01.04.05G</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#A(2)">(2)</span> The Board’s determination of whether a prescription drug has or will create an affordability challenge is not final until the final cost review study report is adopted by the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#A(3)">(3)</span> The public may provide oral and written comments concerning any agenda item of the Board or any decision pending before the Board in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B">B.</span> Final Policy Action: Policy Recommendations and Proposed Regulations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(1)">(1)</span> If the Board makes a final determination that the prescription drug has or will create an affordability challenge, the Board may adopt:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(1)(a)">(a)</span> Non-UPL policy recommendations in accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.05.05" title=".05 Policy Review—Preliminary Policy Recommendations.">Regulation .05 of this chapter</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(1)(b)">(b)</span> Proposed regulations setting the UPL at the specified amount in accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.05.08" title=".08 Establishing and Monitoring a UPL.">Regulation .08 of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(1)(c)">(c)</span> Both.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(2)">(2)</span> The public may provide oral and written comments concerning any agenda item of the Board or any decision pending before the Board in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(3)">(3)</span> Where applicable, the adoption of the final cost review study report, non-UPL policy recommendations, and proposed regulations setting a UPL amount:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(3)(a)">(a)</span> Shall be performed sequentially; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.07#B(3)(b)">(b)</span> May be taken at the same Board meeting.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.08" data-order="|14|01|05|.08|" data-ref-path="14|01|05|.08" class="h__section">.08 Establishing and Monitoring a UPL.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#A">A.</span> Adopting a Proposed Regulation Setting a UPL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#A(1)">(1)</span> The proposed regulation shall set a specified UPL amount for specified eligible governmental entities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#A(2)">(2)</span> The Board and staff shall work with eligible governmental entities to develop the best method for implementing the UPL for the entity and a prospective effective date that provides sufficient time for implementation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#A(3)">(3)</span> The per unit final net cost paid by the eligible governmental entity shall not exceed the GovUPL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#A(4)">(4)</span> The Board shall provide for the automatic suspension of the UPL for the time that the prescription drug product is on the federal Food and Drug Administration prescription drug shortage list by regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#B">B.</span> Monitoring a UPL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#B(1)">(1)</span> The Board shall develop a program for monitoring the availability of any prescription drug product for which it sets a UPL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.08#B(2)">(2)</span> If monitoring discloses a shortage of the prescription drug product in the State, the Board may suspend or modify the UPL.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/14.01.05.09" data-order="|14|01|05|.09|" data-ref-path="14|01|05|.09" class="h__section">.09 Reconsideration.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A">A.</span> Authority to Reconsider UPL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(1)">(1)</span> The Board may reconsider a UPL for any reason.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(2)">(2)</span> If the Board becomes aware of a shortage of a prescription drug product in the State, for a drug that is subject to a UPL, the Board shall reconsider the UPL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(3)">(3)</span> The Board may suspend a UPL at any time and may suspend the UPL for the duration of the reconsideration process by proposing an amended regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(4)">(4)</span> Following completion of the reconsideration process the Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(4)(a)">(a)</span> Take no action and allow the UPL to stand;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(4)(b)">(b)</span> Modify the UPL amount and propose amendment of the UPL regulation setting the new modified UPL amount;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(4)(c)">(c)</span> Suspend the UPL for a specified period and propose amendment of the regulation to proscribe the suspension; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#A(4)(d)">(d)</span> Repeal the UPL and propose repealing the regulation setting the UPL amount.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B">B.</span> Reconsideration Process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)">(1)</span> General Procedures.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(a)">(a)</span> Board staff shall post notice of the reconsideration of the UPL on the Board’s website.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(b)">(b)</span> The Board may solicit patient and stakeholder feedback through written comments submitted in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(4)" title="">COMAR 14.01.01.05B(4)</a> and informational hearings held under <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.06#C" title="">COMAR 14.01.01.06C</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(c)">(c)</span> The Board may use the information gathering process under <a class="internal-link " href="/us/md/exec/comar/14.01.05.04" title=".04 Policy Review—Information Gathering.">Regulation .04 of this chapter</a> to obtain information for the reconsideration process.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(d)">(d)</span> Board staff shall present to the Board:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(d)(i)">(i)</span> The basis for reconsideration;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(d)(ii)">(ii)</span> A summary of the feedback obtained through written comments, informational hearings and the information gathering process, as applicable;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(d)(iii)">(iii)</span> A summary of the information generated through the UPL monitoring program, as applicable;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(d)(iv)">(iv)</span> Estimated impact of the UPL to date such as savings estimates, and estimated impact on access to the drug; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(d)(v)">(v)</span> Staff recommendations for Board action.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(1)(e)">(e)</span> The Board may take any action specified under <a class="internal-link " href="/us/md/exec/comar/14.01.05.09#A(4)" title="">§A(4) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(2)">(2)</span> Modifying a UPL.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(2)(a)">(a)</span> If Board staff recommends further study to support modification of the UPL, the Board shall use the procedures in Regulations .06D-F and .07B(1)(b) of this chapter to develop a new UPL amount and receive public comment.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#B(2)(b)">(b)</span> The Board may modify the UPL amount and propose amendment of the UPL regulation setting the modified UPL amount under § A(4)(b) of this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C">C.</span> Action on Drug where UPL was Repealed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(1)">(1)</span> For any prescription drug product previously subject to a UPL that was later repealed, the Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(1)(a)">(a)</span> Select the prescription drug product for cost review study if the drug product meets the eligibility requirements set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">COMAR 14.01.04.02</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(1)(b)">(b)</span> Conduct a cost review study in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04.05" title=".05 Cost Review Study.">COMAR 14.01.04.05</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(1)(c)">(c)</span> Make a preliminary determination in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.04.05" title=".05 Cost Review Study.">COMAR 14.01.04.05</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(2)">(2)</span> If the Board makes a preliminary determination that the prescription drug product has or will create an affordability challenge the Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(2)(a)">(a)</span> Consider any element or analysis from the original cost review study report;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(2)(b)">(b)</span> If available, consider information from the UPL monitoring program;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(2)(c)">(c)</span> Consider information obtained through the reconsideration process under <a class="internal-link " href="/us/md/exec/comar/14.01.05.09#B" title="">§B of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/14.01.05.09#C(2)(d)">(d)</span> Set a UPL or make other policy recommendations in accordance with Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.05.07" title=".07 Policy Review—Final Policy Action.">.07</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.05.08" title=".08 Establishing and Monitoring a UPL.">.08</a> of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/14.01.06" data-order="|14|01|06|" data-ref-path="14|01|06" class="h__chapter">Chapter 06 Conditions for Payment of Voluntary Assignment of Lottery Prizes Under Judicial Order</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: June 2, 2008 (35:11 Md. R. 1042)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.07" data-order="|14|01|07|" data-ref-path="14|01|07" class="h__chapter">Chapter 07 Agency Procedures Under The Public Information Act</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: May 1, 1981 (8:9 Md. R. 802)</p>
                  <p>Chapter revised effective March 22, 1999 (26:6 Md. R. 487)</p>
                  <p>Regulation .02B amended effective December 17, 2007 (34:25 Md. R. 2214)</p>
                  <p>Regulation .07A amended effective December 17, 2007 (34:25 Md. R. 2214)</p>
                  <p>Regulation .13 amended effective December 17, 2007 (34:25 Md. R. 2214)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.08" data-order="|14|01|08|" data-ref-path="14|01|08" class="h__chapter">Chapter 08 Rules of Procedure for Commission Hearings</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: July 5, 1982 (9:13 Md. R. 1353)</p>
                  <p>Regulation .02 amended effective March 22, 1999 (26:6 Md. R. 487); December 17, 2007 (34:25 Md. R. 2214)</p>
                  <p>Regulation .01 amended effective December 17, 2007 (34:25 Md. R. 2214)</p>
                  <p>Regulation .02A amended effective November 30, 2009 (36:24 Md. R. 1859)</p>
                  <p>Regulation .03B amended effective December 17, 2007 (34:25 Md. R. 2214)</p>
                  <p>Regulation .04B amended effective December 17, 2007 (34:25 Md. R. 2214)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.09" data-order="|14|01|09|" data-ref-path="14|01|09" class="h__chapter">Chapter 09 Open Meetings</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: June 20, 1994 (21:12 Md. R. 1062)</p>
                  <p>Chapter revised effective March 22, 1999 (26:6 Md. R. 487)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.10" data-order="|14|01|10|" data-ref-path="14|01|10" class="h__chapter">Chapter 10 Video Lottery Terminals</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.11 adopted as an emergency provision effective January 23, 2009 (36:4 Md. R. 347); emergency status extended at 36:17 Md. R. 1311</p>
                  <p>Regulations .01—.12 adopted effective November 30, 2009 (36:24 Md. R. 1859)</p>
                  <p>Regulation .01B adopted as an emergency provision effective November 22, 2010 (37:26 Md. R. 1785); adopted permanently effective February 7, 2011 (38:3 Md. R. 152)</p>
                  <p>Regulation .02B amended effective January 25, 2010 (37:2 Md. R. 69)</p>
                  <p>Regulation .02B amended as an emergency provision effective January 26, 2010 (37:3 Md. R. 170); amended permanently effective July 12, 2010 (37:14 Md. R. 939)</p>
                  <p>Regulation .02B amended as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); amended permanently effective November 1, 2010 (37:22 Md. R. 1554)</p>
                  <p>Regulation .03 amended as an emergency provision effective December 28, 2009 (37:3 Md. R. 172); amended permanently effective July 12, 2010 (37:14 Md. R. 939)</p>
                  <p>Regulation .03D amended effective July 25, 2011 (38:15 Md. R. 899)</p>
                  <p>Regulation .03E amended as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); amended permanently effective November 1, 2010 (37:22 Md. R. 1554)</p>
                  <p>Regulation .03E amended as an emergency provision effective December 15, 2010 (38:2 Md. R. 80); amended permanently effective February 21, 2011 (38:4 Md. R. 264)</p>
                  <p>Regulation .05C adopted effective January 25, 2010 (37:2 Md. R. 69)</p>
                  <p>Regulation .13 adopted effective January 25, 2010 (37:2 Md. R. 69)</p>
                  <p>Regulation .13 amended as an emergency provision effective July 2, 2010 (37:16 Md. R. 1058); amended permanently effective October 4, 2010 (37:20 Md. R. 1395)</p>
                  <p>Regulation .13 amended as an emergency provision effective November 23, 2010 (37:26 Md. R. 1785); amended permanently effective January 24, 2011 (38:2 Md. R. 84)</p>
                  <p>Regulation .13C, H amended as an emergency provision effective July 20, 2011 (38:17 Md. R. 1011); amended permanently effective October 17, 2011 (38:21 Md. R. 1280)</p>
                  <p>Regulation .14 adopted effective January 25, 2010 (37:2 Md. R. 69)</p>
                  <p>Regulation .14F amended as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); amended permanently effective November 15, 2010 (37:23 Md. R. 1612)</p>
                  <p>Regulations .15—.17 adopted as an emergency provision effective January 26, 2010 (37:3 Md. R. 170); adopted permanently effective July 12, 2010 (37:14 Md. R. 939)</p>
                  <p>Regulation .15C, F amended as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); amended permanently effective November 15, 2010 (37:23 Md. R. 1612)</p>
                  <p>Regulation .16 amended as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); amended permanently effective November 1, 2010 (37:22 Md. R. 1554)</p>
                  <p>Regulation .16 amended as an emergency provision effective December 15, 2010 (38:2 Md. R. 80); amended permanently effective February 21, 2011 (38:4 Md. R. 264)</p>
                  <p>Regulation .17E, F amended as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); amended permanently effective November 15, 2010 (37:23 Md. R. 1612)</p>
                  <p>Regulation .18 adopted as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); adopted permanently effective November 1, 2010 (37:22 Md. R. 1554)</p>
                  <p>Regulation .18 amended as an emergency provision effective December 15, 2010 (38:2 Md. R. 80); amended permanently effective March 21, 2011 (38:6 Md. R. 396)</p>
                  <p>Regulation .18B amended effective November 26, 2012 (39:23 Md. R. 1532)</p>
                  <p>Regulation .19 adopted as an emergency provision effective May 26, 2010 (37:13 Md. R. 850); adopted permanently effective August 23, 2010 (37:17 Md. R. 1186)</p>
                  <p>Regulation .19 amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); amended permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>Regulation .19 amended effective May 28, 2012 (39:10 Md. R. 661)</p>
                  <p>Regulation .20 adopted as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); adopted permanently effective January 24, 2011 (38:2 Md. R. 84)</p>
                  <p>Regulation .20D amended as an emergency provision effective January 20, 2011 (38:4 Md. R. 263); amended permanently effective April 18, 2011 (38:8 Md. R. 507)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.11" data-order="|14|01|11|" data-ref-path="14|01|11" class="h__chapter">Chapter 11 Video Lottery Facility Operation Licenses</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.06 adopted as an emergency provision effective January 23, 2009 (36:4 Md. R. 347); emergency status extended at 36:17 Md. R. 1311</p>
                  <p>Regulations .01—.06 adopted effective November 30, 2009 (36:24 Md. R. 1859)</p>
                  <p>Regulation .04C amended as an emergency provision effective November 14, 2011 (38:25 Md. R. 1579); amended permanently effective January 23, 2012 (39:1 Md. R. 20)</p>
                  <p>Regulation .04F adopted as an emergency provision effective November 14, 2011 (38:25 Md. R. 1579); adopted permanently effective January 23, 2012 (39:1 Md. R. 20)</p>
                  <p>Regulation .07 adopted as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); amended permanently effective November 15, 2010 (37:23 Md. R. 1612)</p>
                  <p>Regulation .08 adopted as an emergency provision effective August 31, 2010 (37:20 Md. R. 1390); adopted permanently effective November 15, 2010 (37:23 Md. R. 1612)</p>
                  <p>Regulation .08 amended effective January 23, 2012 (39:1 Md. R. 20)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.12" data-order="|14|01|12|" data-ref-path="14|01|12" class="h__chapter">Chapter 12 Video Lottery Terminal Machines</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: January 25, 2010 (37:2 Md. R. 69)</p>
                  <p>Regulation .03 adopted as an emergency provision effective August 31, 2010 (37:20 Md. R. 1391); adopted permanently effective October 4, 2010 (37:20 Md. R. 1395)</p>
                  <p>Regulation .04A amended effective November 26, 2012 (39:23 Md. R. 1532)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.13" data-order="|14|01|13|" data-ref-path="14|01|13" class="h__chapter">Chapter 13 Facility Standards</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: August 23, 2010 (37:17 Md. R. 1186)</p>
                  <p>Regulation .02 amended as an emergency provision effective May 10, 2011 (38:13 Md. R. 754); amended permanently effective September 5, 2011 (38:18 Md. R. 1078)</p>
                  <p>Regulation .03A amended effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.14" data-order="|14|01|14|" data-ref-path="14|01|14" class="h__chapter">Chapter 14 Video Lottery Facility Minimum Internal Control Standards</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: August 23, 2010 (37:17 Md. R. 1186)</p>
                  <p>Regulation .04C amended effective December 24, 2012 (39:25 Md. R. 1615)</p>
                  <p>Regulation .05A amended effective June 27, 2011 (38:13 Md. R. 756)</p>
                  <p>Regulation .08F amended effective December 24, 2012 (39:25 Md. R. 1615)</p>
                  <p>Regulation .16B amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); amended permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>Regulation .17 amended effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>Regulation .20I amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); amended permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>Regulation .36B amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); amended permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>Regulation .37A,D,E amended effective December 24, 2012 (39:25 Md. R. 1615)</p>
                  <p>Regulation .37B amended effective May 28, 2012 (39:10 Md. R. 661)</p>
                  <p>Regulation .37F—H adopted effective May 28, 2012 (39:10 Md. R. 661)</p>
                  <p>Regulation .38C, E amended effective December 24, 2012 (39:25 Md. R. 1615)</p>
                  <p>Regulation .44 amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); amended permanently effective January 24, 2011 (38:2 Md. R. 84)</p>
                  <p>Regulation .45B amended effective December 24, 2012 (39:25 Md. R. 1615)</p>
                  <p>Regulation .46 amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); amended permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>Regulation .47B, C amended effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>Regulation .50 adopted effective December 24, 2012 (39:25 Md. R. 1615)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.15" data-order="|14|01|15|" data-ref-path="14|01|15" class="h__chapter">Chapter 15 Video Lottery Technical Standards</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.33 adopted as an emergency provision effective May 26, 2010 (37:13 Md. R. 850); adopted permanently effective August 23, 2010 (37:17 Md. R. 1186)</p>
                  <p>Regulation .11C amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); amended permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>Regulation .18 amended as an emergency provision effective October 13, 2010 (37:23 Md. R. 1608); amended permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.16" data-order="|14|01|16|" data-ref-path="14|01|16" class="h__chapter">Chapter 16 Voluntary Exclusion and Responsible Gaming</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.10 adopted as an emergency provision effective July 2, 2010 (37:16 Md. R. 1059); adopted permanently effective October 4, 2010 (37:20 Md. R. 1395)</p>
                  <p>Regulation .03 amended effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>Regulation .04 amended effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>Regulation .08 amended effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>Regulation .09A amended effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>Regulation .09B amended effective June 27, 2011 (38:13 Md. R. 756)</p>
                  <p>Regulation .11 adopted effective April 16, 2012 (39:7 Md. R. 495)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.17" data-order="|14|01|17|" data-ref-path="14|01|17" class="h__chapter">Chapter 17 Mandatory Exclusion</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.09 adopted as an emergency provision effective August 31, 2010 (37:20 Md. R. 1391); adopted permanently effective October 4, 2010 (37:20 Md. R. 1395)</p>
                  <p>Regulation .09C amended effective June 27, 2011 (38:13 Md. R. 756)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.18" data-order="|14|01|18|" data-ref-path="14|01|18" class="h__chapter">Chapter 18 Violations, Civil Penalties, and Sanctions</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.06 adopted as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); adopted permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>Regulation .03D adopted as an emergency provision effective November 14, 2011 (38:25 Md. R. 1579); adopted permanently effective January 23, 2012 (39:1 Md. R. 20)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.19" data-order="|14|01|19|" data-ref-path="14|01|19" class="h__chapter">Chapter 19 Collection of Taxes, Fees, and Civil Penalties</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.04 adopted as an emergency provision effective October 13, 2010 (37:23 Md. R. 1607); adopted permanently effective December 27, 2010 (37:26 Md. R. 1789)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
                <h2 id="/us/md/exec/comar/14.01.20" data-order="|14|01|20|" data-ref-path="14|01|20" class="h__chapter">Chapter 20 Unannounced Inspections</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations .01—.04 adopted as an emergency provision effective November 22, 2010 (37:26 Md. R. 1785); adopted permanently effective February 7, 2011 (38:3 Md. R. 152)</p>
                  <p>——————</p>
                  <p>Chapter repealed as an emergency provision effective March 1, 2013 (40:7 Md. R. 608)</p>
                </section>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/14" aria-label="Title 14 INDEPENDENT AGENCIES">
                <div class="h__ui">Previous</div>
                <span>Title 14 INDEPENDENT AGENCIES</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/14.02" aria-label="Subtitle 02 STATE PUBLIC INFORMATION ACT COMPLIANCE BOARD">
                <div class="h__ui">Next</div>
                <span>Subtitle 02 STATE PUBLIC INFORMATION ACT COMPLIANCE BOARD</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">

<p>
      Please do not scrape. Instead, bulk download the CC-BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
